US20160031946A1 - Multi-epitopic vaccine - Google Patents
Multi-epitopic vaccine Download PDFInfo
- Publication number
- US20160031946A1 US20160031946A1 US14/883,668 US201514883668A US2016031946A1 US 20160031946 A1 US20160031946 A1 US 20160031946A1 US 201514883668 A US201514883668 A US 201514883668A US 2016031946 A1 US2016031946 A1 US 2016031946A1
- Authority
- US
- United States
- Prior art keywords
- seq
- cells
- polypeptide
- antigen
- zebra
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960005486 vaccine Drugs 0.000 title description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 121
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 106
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 103
- 229920001184 polypeptide Polymers 0.000 claims abstract description 86
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 54
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 52
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 41
- 241000283070 Equus zebra Species 0.000 claims abstract description 28
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 18
- 239000012634 fragment Substances 0.000 claims abstract description 18
- 238000010361 transduction Methods 0.000 claims abstract description 16
- 230000026683 transduction Effects 0.000 claims abstract description 16
- 102000036639 antigens Human genes 0.000 claims description 79
- 108091007433 antigens Proteins 0.000 claims description 79
- 239000000427 antigen Substances 0.000 claims description 78
- 210000004443 dendritic cell Anatomy 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 50
- 201000011510 cancer Diseases 0.000 claims description 40
- 201000010099 disease Diseases 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 35
- 108091054437 MHC class I family Proteins 0.000 claims description 25
- 150000001413 amino acids Chemical group 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 230000004044 response Effects 0.000 claims description 20
- 244000052769 pathogen Species 0.000 claims description 18
- 108091054438 MHC class II family Proteins 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 16
- 230000001717 pathogenic effect Effects 0.000 claims description 14
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 230000000890 antigenic effect Effects 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 13
- 102000043129 MHC class I family Human genes 0.000 claims description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 10
- 230000001900 immune effect Effects 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 9
- 230000000087 stabilizing effect Effects 0.000 claims description 8
- 102000043131 MHC class II family Human genes 0.000 claims description 7
- 230000001419 dependent effect Effects 0.000 claims description 7
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 230000005784 autoimmunity Effects 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 238000011122 anti-angiogenic therapy Methods 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 239000013592 cell lysate Substances 0.000 claims description 2
- 230000006037 cell lysis Effects 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 238000002626 targeted therapy Methods 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 19
- 238000009169 immunotherapy Methods 0.000 abstract description 13
- 230000002265 prevention Effects 0.000 abstract description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 55
- 108020001507 fusion proteins Proteins 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 22
- 238000002255 vaccination Methods 0.000 description 21
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 20
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 20
- 102000037865 fusion proteins Human genes 0.000 description 19
- 108700028369 Alleles Proteins 0.000 description 18
- 108700002563 poly ICLC Proteins 0.000 description 18
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 17
- 102000004127 Cytokines Human genes 0.000 description 17
- 108090000695 Cytokines Proteins 0.000 description 17
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 14
- 108091008874 T cell receptors Proteins 0.000 description 14
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 14
- 108010002350 Interleukin-2 Proteins 0.000 description 13
- 102100020873 Interleukin-2 Human genes 0.000 description 13
- -1 TAG-2 Proteins 0.000 description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 201000001441 melanoma Diseases 0.000 description 11
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 10
- 108010058846 Ovalbumin Proteins 0.000 description 10
- 238000011068 loading method Methods 0.000 description 10
- 229940092253 ovalbumin Drugs 0.000 description 10
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 9
- 238000011740 C57BL/6 mouse Methods 0.000 description 9
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 9
- 239000012648 POLY-ICLC Substances 0.000 description 9
- 210000001185 bone marrow Anatomy 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 229940115270 poly iclc Drugs 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 8
- 101000854908 Homo sapiens WD repeat-containing protein 11 Proteins 0.000 description 8
- 241000701806 Human papillomavirus Species 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 8
- 102100020705 WD repeat-containing protein 11 Human genes 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 210000004988 splenocyte Anatomy 0.000 description 8
- 238000011830 transgenic mouse model Methods 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 7
- 210000002307 prostate Anatomy 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 102100038196 Chitinase-3-like protein 1 Human genes 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 241000590002 Helicobacter pylori Species 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 6
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 6
- 206010035664 Pneumonia Diseases 0.000 description 6
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 229940037467 helicobacter pylori Drugs 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- 108090000204 Dipeptidase 1 Proteins 0.000 description 5
- 101001005718 Homo sapiens Melanoma-associated antigen 2 Proteins 0.000 description 5
- 102100025081 Melanoma-associated antigen 2 Human genes 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 5
- 241000725643 Respiratory syncytial virus Species 0.000 description 5
- 102000006635 beta-lactamase Human genes 0.000 description 5
- 206010017758 gastric cancer Diseases 0.000 description 5
- 208000002672 hepatitis B Diseases 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 description 4
- 101710109241 E3 ubiquitin-protein ligase RNF43 Proteins 0.000 description 4
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 208000005176 Hepatitis C Diseases 0.000 description 4
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 4
- 101000938346 Homo sapiens Ephrin type-A receptor 2 Proteins 0.000 description 4
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 description 4
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 4
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 description 4
- 241000579048 Merkel cell polyomavirus Species 0.000 description 4
- 102100034256 Mucin-1 Human genes 0.000 description 4
- 108010008707 Mucin-1 Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- 241000700647 Variola virus Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 208000005017 glioblastoma Diseases 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 206010042863 synovial sarcoma Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 102100022884 ADP-ribosylation factor-like protein 4D Human genes 0.000 description 3
- 241000193738 Bacillus anthracis Species 0.000 description 3
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 3
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 241000606153 Chlamydia trachomatis Species 0.000 description 3
- 208000001490 Dengue Diseases 0.000 description 3
- 206010012310 Dengue fever Diseases 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 3
- 101000974385 Homo sapiens ADP-ribosylation factor-like protein 4D Proteins 0.000 description 3
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 3
- 101000796203 Homo sapiens L-dopachrome tautomerase Proteins 0.000 description 3
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 description 3
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 3
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 3
- 208000016604 Lyme disease Diseases 0.000 description 3
- 108010029973 Lymphocytic choriomeningitis virus glycoprotein peptide Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102100037020 Melanoma antigen preferentially expressed in tumors Human genes 0.000 description 3
- 101710178381 Melanoma antigen preferentially expressed in tumors Proteins 0.000 description 3
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 3
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 description 3
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 3
- 241000588650 Neisseria meningitidis Species 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 3
- 102100038358 Prostate-specific antigen Human genes 0.000 description 3
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 3
- 102100037421 Regulator of G-protein signaling 5 Human genes 0.000 description 3
- 101710140403 Regulator of G-protein signaling 5 Proteins 0.000 description 3
- 241000702670 Rotavirus Species 0.000 description 3
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 3
- 101710185775 Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 description 3
- 101710155955 U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000005809 anti-tumor immunity Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229960001714 calcium phosphate Drugs 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229940038705 chlamydia trachomatis Drugs 0.000 description 3
- 208000025729 dengue disease Diseases 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000005252 hepatitis A Diseases 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 102000013563 Acid Phosphatase Human genes 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 2
- 208000004881 Amebiasis Diseases 0.000 description 2
- 206010001980 Amoebiasis Diseases 0.000 description 2
- 241001465677 Ancylostomatoidea Species 0.000 description 2
- 102100023003 Ankyrin repeat domain-containing protein 30A Human genes 0.000 description 2
- 101100111141 Arabidopsis thaliana GALT3 gene Proteins 0.000 description 2
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 2
- 101710131520 B melanoma antigen 1 Proteins 0.000 description 2
- 208000004429 Bacillary Dysentery Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108010085074 Brevican Proteins 0.000 description 2
- 102100032312 Brevican core protein Human genes 0.000 description 2
- 208000006448 Buruli Ulcer Diseases 0.000 description 2
- 208000023081 Buruli ulcer disease Diseases 0.000 description 2
- 206010007048 Campylobacter gastroenteritis Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 108010066813 Chitinase-3-Like Protein 1 Proteins 0.000 description 2
- 102100038731 Chitinase-3-like protein 2 Human genes 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 102100032368 Coiled-coil domain-containing protein 110 Human genes 0.000 description 2
- 102100024342 Contactin-2 Human genes 0.000 description 2
- 208000000307 Crimean Hemorrhagic Fever Diseases 0.000 description 2
- 201000003075 Crimean-Congo hemorrhagic fever Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 208000030820 Ebola disease Diseases 0.000 description 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 2
- 102000003967 Fibroblast growth factor 5 Human genes 0.000 description 2
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 2
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000022555 Genital disease Diseases 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 206010061192 Haemorrhagic fever Diseases 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000757191 Homo sapiens Ankyrin repeat domain-containing protein 30A Proteins 0.000 description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 2
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 2
- 101000883325 Homo sapiens Chitinase-3-like protein 2 Proteins 0.000 description 2
- 101000868824 Homo sapiens Coiled-coil domain-containing protein 110 Proteins 0.000 description 2
- 101000909516 Homo sapiens Contactin-2 Proteins 0.000 description 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 2
- 101001036406 Homo sapiens Melanoma-associated antigen C1 Proteins 0.000 description 2
- 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000813738 Homo sapiens Transcription factor ETV6 Proteins 0.000 description 2
- 101000814512 Homo sapiens X antigen family member 1 Proteins 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 201000005807 Japanese encephalitis Diseases 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- 102100034872 Kallikrein-4 Human genes 0.000 description 2
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 2
- 206010023927 Lassa fever Diseases 0.000 description 2
- 208000004554 Leishmaniasis Diseases 0.000 description 2
- 206010024238 Leptospirosis Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 108010031030 Mammaglobin A Proteins 0.000 description 2
- 102000005727 Mammaglobin A Human genes 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 102100039447 Melanoma-associated antigen C1 Human genes 0.000 description 2
- 102100027252 Melanoma-associated antigen C2 Human genes 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100023123 Mucin-16 Human genes 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 241000187917 Mycobacterium ulcerans Species 0.000 description 2
- 206010066289 Mycobacterium ulcerans infection Diseases 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 206010035148 Plague Diseases 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 208000000705 Rift Valley Fever Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102100021466 Sarcoma antigen 1 Human genes 0.000 description 2
- 101710199699 Sarcoma antigen 1 Proteins 0.000 description 2
- 206010040550 Shigella infections Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102100022441 Sperm surface protein Sp17 Human genes 0.000 description 2
- 101710176444 Sperm surface protein Sp17 Proteins 0.000 description 2
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 2
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 2
- 102100039580 Transcription factor ETV6 Human genes 0.000 description 2
- 208000034784 Tularaemia Diseases 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-alpha-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 241000710886 West Nile virus Species 0.000 description 2
- 102100039490 X antigen family member 1 Human genes 0.000 description 2
- 208000003152 Yellow Fever Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000000688 enterotoxigenic effect Effects 0.000 description 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 2
- 101150079015 esxB gene Proteins 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 208000001786 gonorrhea Diseases 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 201000010284 hepatitis E Diseases 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 108010024383 kallikrein 4 Proteins 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 201000004409 schistosomiasis Diseases 0.000 description 2
- 201000005113 shigellosis Diseases 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 108010042703 synovial sarcoma X breakpoint proteins Proteins 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 206010044325 trachoma Diseases 0.000 description 2
- 108091006106 transcriptional activators Proteins 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- AHOKKYCUWBLDST-QYULHYBRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=CC=C1 AHOKKYCUWBLDST-QYULHYBRSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 102100037982 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Human genes 0.000 description 1
- 101710170638 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Proteins 0.000 description 1
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- 101000719121 Arabidopsis thaliana Protein MEI2-like 1 Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 101150009389 BZLF1 gene Proteins 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 241000588780 Bordetella parapertussis Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108010008629 CA-125 Antigen Proteins 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 101710120595 Cancer/testis antigen 2 Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 101710190849 Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000759568 Corixa Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102000002140 Fatty Acid-Binding Protein 7 Human genes 0.000 description 1
- 108010001387 Fatty Acid-Binding Protein 7 Proteins 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102100039860 G-protein coupled receptor 143 Human genes 0.000 description 1
- 101710104677 G-protein coupled receptor 143 Proteins 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010012015 GVYDGREHTV Proteins 0.000 description 1
- 108060003306 Galactosyltransferase Proteins 0.000 description 1
- 102000030902 Galactosyltransferase Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 102100021700 Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 Human genes 0.000 description 1
- 108010065192 HER2p63 peptide Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000896564 Homo sapiens Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 Proteins 0.000 description 1
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000971605 Homo sapiens Kita-kyushu lung cancer antigen 1 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101000620554 Homo sapiens Ras-related protein Rab-38 Proteins 0.000 description 1
- 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 101600082430 Homo sapiens Vascular endothelial growth factor A (isoform VEGF165) Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 102100037920 Insulin-like growth factor 2 mRNA-binding protein 3 Human genes 0.000 description 1
- 101710126182 Insulin-like growth factor 2 mRNA-binding protein 3 Proteins 0.000 description 1
- 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 description 1
- 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 description 1
- 102000004559 Interleukin-13 Receptors Human genes 0.000 description 1
- 108010017511 Interleukin-13 Receptors Proteins 0.000 description 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 1
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100021533 Kita-kyushu lung cancer antigen 1 Human genes 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 108010059255 MAGE-A10 antigen Proteins 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 101710105759 Major outer membrane porin Proteins 0.000 description 1
- 101710164702 Major outer membrane protein Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 206010027260 Meningitis viral Diseases 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- ICTPRLMOGAKCOZ-HWVMREAWSA-N NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O)C(C)C)CC1=CC=C(O)C=C1 Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O)C(C)C)CC1=CC=C(O)C=C1 ICTPRLMOGAKCOZ-HWVMREAWSA-N 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 102100034441 Neuroligin-4, X-linked Human genes 0.000 description 1
- 101710083717 Neuroligin-4, X-linked Proteins 0.000 description 1
- 101710130688 Neuronal cell adhesion molecule Proteins 0.000 description 1
- 102100021852 Neuronal cell adhesion molecule Human genes 0.000 description 1
- LBGQSUBECNOFFN-HNQUOIGGSA-N OCCC(=O)CN\C=C\C(O)=O Chemical compound OCCC(=O)CN\C=C\C(O)=O LBGQSUBECNOFFN-HNQUOIGGSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 102100022305 Ras-related protein Rab-38 Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 208000006257 Rinderpest Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001312524 Streptococcus viridans Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 241000202921 Ureaplasma urealyticum Species 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102300041083 Vascular endothelial growth factor A isoform VEGF165 Human genes 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 108010039524 chondroitin sulfate proteoglycan 4 Proteins 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 108010051081 dopachrome isomerase Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 230000002449 erythroblastic effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 108010002182 glycyl-phenylalanyl-lysyl-glutaminyl-seryl-seryl-lysyl-alanyl-leucine Proteins 0.000 description 1
- 108010014242 gp100(17-25) peptide Proteins 0.000 description 1
- 108010072094 gp100(280-288) melanoma antigen peptide Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 108091005020 human MAGE-A1 protein (278-286) Proteins 0.000 description 1
- 102000028650 human MAGE-A1 protein (278-286) Human genes 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 101150076681 mpt63 gene Proteins 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000007126 proinflammatory cytokine response Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000007398 protein translocation Effects 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229950010550 resiquimod Drugs 0.000 description 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 229960000714 sipuleucel-t Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 108010044720 telomerase reverse transcriptase (540-548) Proteins 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 201000010044 viral meningitis Diseases 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 229940023148 viral-based vaccine Drugs 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464492—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16233—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16241—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a multi-epitopic vaccine and its use in immunotherapy including prevention and/or treatment of cancers or infectious diseases.
- Immunotherapy is gaining importance for the treatment and prevention of various human diseases, including infectious diseases and cancers.
- CTLs cytotoxic T lymphocytes
- Tumor-associated antigens recognized by CTLs are 8 to 11 residue peptides called CD8 + epitopes which are bound to MHC class I molecules and displayed at the tumor cell surface.
- TSA tumor specific antigens
- TAAs tumor-associated antigens
- the main goal of current research on immunotherapy approaches is to elicit potent anti-tumor immunity after therapeutic vaccination against these antigens.
- Approaches widely developed and transferred to clinical trials include peptide vaccination and adoptive immunotherapy with ex-vivo loaded dendritic cells (DCs).
- CD4 + helper T cells has been described in anti-tumor immunity. Indeed, it has been reported that this CD4 compartment plays a crucial role in mounting an efficient anti-tumoral immune response (Bos and Sherman, 2010 , Cancer Res. 70:8368-8377).
- Th cells are also involved in the maintenance of long-lasting cellular immunity (immunological memory), and tumor infiltration by Th cells is an essential step for the recruitment and function of CTLs.
- Tumor-associated antigens recognized by Th cells are typically 12-25 residue peptides (although some are much longer) called CD4 + epitopes which are bound to MHC class II molecules and displayed at the tumor cell surface.
- Different vectors have been developed and evaluated to deliver different MHC class I restricted epitopes; these include viral vectors (Durantez et al., 2009, Scand. J. Immunol 69:80-89; Mateo et al., 1999, J. Immunol. 163:4058-4063; Tine et al., 2005, Vaccine 23:1085-1091), cDNA-based vaccine (Ishioka et al., 1999, J. Immunol. 162:3915-3925; Scardino et al., 2007, Cancer Res. 67:7028-7036) and mRNA electroporated dendritic cells (Waeckerle-Men et al., 2006, Cancer Immunol. Immunother. 55:1524-1533).
- viral vectors Durantez et al., 2009, Scand. J. Immunol 69:80-89; Mateo et al., 1999, J. Immunol. 163:4058-4063; Tine
- vaccinia virus vectors encoding multiple epitopes associated with infectious diseases (Thomson et al., 1996, J. Immunol. 157:822-826; Thomson et al., 1995, Proc. Natl. Acad. Sci.
- vaccinia virus vectors encoded antigens are preferentially presented by MHC class I restricted molecules; second, there is a limitation of the size of insert; third, there is rapid degradation of the encoded antigens, and finally there are many regulatory hurdles for clinical translation.
- PTDs protein transduction domains
- HAV TAT human immunodeficiency virus transactivating regulatory protein
- penetratin Antennapedia homeodomain
- VP22 Herpes simplex virus
- polyR synthetic polyarginine
- TAT The most widely studied PTD, TAT, was fused to different antigens and used to transduce dendritic cells (in virtually all studies) before testing immunogenicity in vivo (Brooks et al., 2010 , Biochimica et Biophysica Acta 1805:25-34).
- a CTL-mediated immune response i.e. mediated by CD8 T cells and restricted by MHC class I
- CD8 T cells mediated by CD8 T cells and restricted by MHC class I
- CD4 T cells were also implicated.
- vaccination with TAT fused to TRP2 resulted in long-term protection as shown in tumor-free mice re-challenged with the tumor, suggesting a superior memory response.
- TAT TAT based vaccines directly in vivo without prior transduction of DCs
- the second is that the nature of the cargo transported into the cell by TAT influences intracellular localisation; large TAT-fusion proteins can remain entrapped in endosomes where they are degraded, which is predicted to limit access to the cross-presentation pathway resulting in poor stimulation of CD8 T cells (Tünnemann et al., 2006, FASEB J., 20: 1775-1784).
- the present invention solves this problem by providing a PTD fusion protein allowing efficient delivery and presentation of multiple CD4 + - and CD8 + -restricted epitopes.
- the multi-epitopic PTD fusion protein of the invention thus, is useful in immunotherapy for treating and/or preventing cancers or infectious diseases.
- a first aspect of the invention provides an isolated polypeptide comprising:
- a second aspect of the invention provides an isolated polynucleotide encoding a polypeptide of the invention, a recombinant vector comprising said polynucleotide, as well as a host cell comprising said recombinant vector.
- a third aspect of the invention provides antigen presenting cells loaded with a polypeptide of the invention.
- a fourth aspect of the invention provides a vaccine composition comprising a polypeptide of the invention or antigen presenting cells of the invention, for preventing, treating, or stabilizing cancers or infectious diseases.
- a fifth aspect of the invention provides a use of a polypeptide of the invention or the use of antigen presenting cells loaded with a polypeptide of the invention in the manufacture of a medicament.
- a sixth aspect of the invention provides a method of preventing, treating or stabilizing a cancer or an infectious disease in a subject said method comprising administering in a subject in need thereof a therapeutically effective amount of a polypeptide of the invention or antigen presenting cells of the invention, and at least one pharmaceutically acceptable carrier.
- a seventh aspect of the invention provides a method for eliciting or improving, in a subject, an immunologic response against multiple epitopes that is dependent on CD4 + helper T cells and CD8 + cytotoxic T cells, wherein said method comprises administering either a polypeptide of the invention or antigen presenting cells of the invention to said subject.
- An eighth aspect of the invention provides a method for eliciting or improving, in a subject, an immunologic response against multiple epitopes that is restricted by multiple MHC class I molecules and multiple MHC class II molecules, wherein said method comprises administering either a polypeptide of the invention or antigen presenting cells of the invention to said subject.
- FIG. 1 shows different ZEBRA-fusion proteins used in the experimental section.
- Construct 1 ZEBRA- ⁇ -lactamase: encodes ⁇ -lactamase from E. Coli deleted for the secretion signal (residues 1-23) and residue 24 His was changed to Asp to create an optimal Kozak sequence.
- Construct 2 ZEBRA-OVA: encodes a truncated form of the chicken ovalbumin (OVA 234-386 ). This construction contains both CD8 epitope OVA 257-264 and CD4 epitope OVA 323-339 .
- Construct 3 ZEBRA-MultiE: encodes a chimeric protein with three CD8 epitopes from the ovalbumin OVA 257-264 , from lymphocytic choriomengitis virus glycoprotein LCMV-GP 33-41 and from the murine tumor-associated antigen GP100 25-33 and two CD4 epitopes: OVA 323-339 and LCMV-GP 61-80 .
- the spacers between each epitope are the natural flanking 4 amino acid residues.
- FIG. 2 shows CD8 + multi-epitopic presentation after ZEBRA-multiE fusion protein loading into DCs.
- Bone marrow dendritic cells from C57BL/6 mice were loaded with 0.3 ⁇ M ZEBRA-MultiE during 4 h and matured overnight with a cocktail containing IFN ⁇ , IFN ⁇ , IL-4 and PolyIC.
- CFSE stained CD8 T cells from either OT-1, Pmel or P14 mice were added at a ratio 10:1. After 5 days of proliferation, dilution of CFSE was monitored by flow cytometry.
- FIG. 3 shows CD4 + multi-epitopic presentation after ZEBRA-multiE fusion protein loading into DCs.
- Bone marrow dendritic cells from C57BL/6 mice were loaded with 0.3 ⁇ M ZEBRA-MultiE during 4 h and matured overnight with a cocktail containing IFN ⁇ , IFN ⁇ , IL-4 and PolyIC.
- CFSE stained CD4 T cells from either OT-2 or SMARTA mice were added at a ratio 10:1. After 5 days of proliferation, dilution of CFSE was monitored by flow cytometry.
- FIG. 4 shows effector function of T cells primed in vitro by DCs loaded with ZEBRA-MultiE fusion protein.
- Bone marrow dendritic cells from C57BL/6 mice were loaded with 0.3 ⁇ M ZEBRA-MultiE during 4 h and matured overnight with a cocktail containing IFN ⁇ , IFN ⁇ , IL-4 and PolyIC.
- CFSE stained CD8 T cells from either OT-1, Pmel or P14 mice and CD4 T cells from either OT-2 or SMARTA mice were added at a ratio 10:1. After 5 days of proliferation, the supernatant was tested for cytokine expression using the Multiplex cytokine detection kits (BD Biosciences Pharmingen, San Diego, Calif.) and analyzed by flow cytometry.
- FIG. 5 shows the results of vaccination of mice with DCs loaded with ZEBRA-MultiE fusion protein.
- C57BL/6 mice were vaccinated subcutaneously twice with a 14 days of interval with 1 ⁇ 10 6 mature dendritic cells loaded with ZEBRA-MultiE. 7 days after the last vaccination, splenocytes were recovered and re-stimulated during 7 days with 10 ⁇ M of the respective peptides.
- the T cells were re-stimulated with 10 ⁇ M of the respective peptide during 4 h and intracellular staining for IFN ⁇ , TNF ⁇ and IL-2 was performed and analyzed by flow cytometry. Multi-functional analysis was performed with SPICE (Roeder et al, 2011, Cytometry, 79A:167-174). The figures show the percentage of positive cells gated on CD8+ or CD4+ T cells, respectively.
- FIG. 6 shows the results of vaccination of mice with ZEBRA-MultiE fusion protein.
- C57BL/6 mice were vaccinated subcutaneously twice with a 14 days of interval with 2 ⁇ 6 ⁇ g ZEBRA-MultiE and 100 ⁇ g PolyIC. 7 days after the last vaccination, splenocytes were recovered and re-stimulated during 7 days with 10 ⁇ M of the respective peptides. The T cells were re-stimulated with 10 ⁇ M of the respective peptide during 4 h and intracellular staining for IFN ⁇ , TNF ⁇ and IL-2 was performed and analyzed by flow cytometry. Multi-functional analysis was performed with SPICE.
- FIG. 7 shows that Zebra-MultiE can be processed and presented by dendritic cells with different MHC molecules.
- Bone marrow derived dendritic cells from mice on BALB/c background were loaded for 4 h with 0.3 ⁇ M Zebra-MultiE and matured overnight with poly ICLC (Hiltonol®).
- Zebra-MultiE loaded and matured dendritic cells were co-incubated with CFSE stained splenocytes from DO11.10 TCR transgenic mice in which all of the CD4 + T cells are specific for the immunodominant ovalbumin epitope OVA 257-264 .
- Negative control splenocytes were incubated with non-loaded dendritic cells.
- Positive control dendritic cells were pulsed with peptide. After five days of culture, T cell proliferation by CFSE dilution was monitored by flow cytometry.
- FIG. 8 shows that Zebra-MultiE translocates into endogenous dendritic cells in vivo, is processed leading to cross-presentation on MHC class I molecules.
- mice were vaccinated with PBS (negative control), 200 ⁇ g peptides and 100 ⁇ g anti-CD40 subcutaneously and 50 ⁇ g Poly ICLC (Hiltonol®) intramuscularly (positive control) or 10 ⁇ g ZEBRA-MultiE protein and 100 ⁇ g anti-CD40 subcutaneously and 50 ⁇ g Poly ICLC (Hiltonol®) intramuscularly.
- PBS negative control
- Poly ICLC Hiltonol® intramuscularly
- 10 ⁇ g ZEBRA-MultiE protein 10 ⁇ g ZEBRA-MultiE protein and 100 ⁇ g anti-CD40 subcutaneously and 50 ⁇ g Poly ICLC (Hiltonol®) intramuscularly.
- 1.5 ⁇ 10 6 CFSE stained splenocytes from either P14 or OT1 TCR transgenic mice were adoptively transferred by intravenous injection.
- Four days after vaccination/adoptive transfer the mice were sacrificed and proliferation of adoptively transferred T cell from draining lymph nodes was assessed by
- FIG. 9 shows that vaccination of mouse with ZEBRA-MultiE can induce polyclonal immune responses.
- mice were vaccinated twice at 14-days of interval by subcutaneous injection of 10 ⁇ g ZEBRA-MultiE protein and 100 ⁇ g anti-CD40 and intramuscular injection of 50 ⁇ g Poly ICLC (Hiltonol®). Seven days after the boost, the mice were sacrificed and the percentages of CD8 + T cells specific for either OVA 323-339 , LCMV-GP 33-41 , or GP100 25-33 were assessed in the draining lymph nodes by tetramer staining.
- ZEBRA also known as Zta, Z, EB1, or BZLF1
- BZIP basic-leucine zipper
- EBV Epstein—Barr virus
- MD minimal domain
- any fragment of the minimal domain mentioned above such as a fragment comprising or consisting of amino acid sequence SEQ ID NO: 8, or any peptide with a similar amino acid sequence as ZEBRA or ZEBRA fragment, provided said fragment or similar peptide still retains the capacity of internalization.
- the amino acid sequence of ZEBRA is disclosed under NCBI accession number YP — 401673.
- epitope also known as “antigenic determinant” is the part of an antigen that is recognized by the immune system, specifically by antibodies, B cells, or T cells.
- epitope is mainly used to designate T cell epitopes, which are presented on the surface of an antigen-presenting cell, where they are bound to Major Histocompatibility Complex (MHC).
- MHC Major Histocompatibility Complex
- T cell epitopes presented by MHC class I molecules are typically, but not exclusively, peptides between 8 and 11 amino acids in length, whereas MHC class II molecules present longer peptides, generally, but not exclusively, between 12 and 25 amino acids in length.
- CD4 epitope or “CD4 + -restricted epitope” designates, herewith, an epitope recognized by a CD4 T cell, said epitope consisting of an antigen fragment lying in the groove of a MHC class II molecule.
- CD8 + epitope or “CD8 + -restricted epitope” designates, herewith, an epitope recognized by a CD8 + T cell, said epitope consisting of an antigen fragment lying in the groove of a MHC class I molecule.
- MHC class I designates one of the two primary classes of the Major Histocompatibility Complex molecules.
- the MHC class I (also noted “MHC I”) molecules are found on every nucleated cell of the body.
- the function of MHC class I is to display an epitope to cytotoxic cells (CTLs).
- CTLs cytotoxic cells
- MHC class I molecules consist of two polypeptide chains, ⁇ - and ⁇ 2-microglobulin (b2m). Only the ⁇ chain is polymorphic and encoded by a HLA gene, while the b2m subunit is not polymorphic and encoded by the Beta-2 microglobulin gene.
- MHC class II designates the other primary class of the Major Histocompatibility Complex molecules.
- the MHC class II also noted “MHC II” molecules are found only on a few specialized cell types, including macrophages, dendritic cells and B cells, all of which are professional antigen-presenting cells (APCs).
- APCs professional antigen-presenting cells
- Tumor epitope means, herewith, an epitope from a tumor-associated antigen or from a tumor-specific antigen. Examples of tumor-associated and tumor-specific epitopes are provided in Tables 1-4.
- “Pathogen epitope” means, herewith, an epitope from an antigenic protein from a pathogen including viruses, bacteria, fungi, protozoa and multicellular parasites.
- Antigenic proteins from pathogens include, herewith, proteins from pathogens responsible of diseases which can be a target for vaccination including, for instance, Amoebiasis, Anthrax, Buruli Ulcer ( Mycobacterium ulcerans ), Caliciviruses associated diarrhoea, Campylobacter diarrhoea, Cervical Cancer (Human papillomavirus), Chlamydia trachomatis associated genital diseases, Cholera, Crimean-Congo haemorrhagic fever, Dengue Fever, Diptheria, Ebola haemorrhagic fever, Enterotoxigenic Escherichia coli (ETEC) diarrhoea, Gastric Cancer ( Helicobacter pylori ), Gonorrhea, Group A Str
- treatment and “treating” and the like generally mean obtaining a desired pharmacological and physiological effect.
- the effect may be prophylactic in terms of preventing or partially preventing a disease, symptom or condition thereof and/or may be therapeutic in terms of a partial or complete cure of a disease, condition, symptom or adverse effect attributed to the disease.
- treatment covers any treatment of a disease in a mammal, particularly a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it such as a preventive early asymptomatic intervention; (b) inhibiting the disease, i.e., arresting its development; or relieving the disease, i.e., causing regression of the disease and/or its symptoms or conditions such as improvement or remediation of damage.
- the methods, uses, formulations and compositions according to the invention are useful in the treatment of cancers or infectious diseases and/or in the prevention of evolution of cancers into an advanced or metastatic stage in patients with early stage cancer, thereby improving the staging of the cancer.
- prevention of a disease or disorder includes the prevention of the appearance or development of a cancer in an individual identified as at risk of developing said cancer, for instance due to past occurrence of said cancer in the circle of the individual's relatives, and prevention of infection with tumor promoting pathogens such as, for example, Epstein-Barr virus (EBV), Human papillomavirus (HPV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human Herpes virus 8 (HHV8), human T-cell leukemia virus type 1 (HTLV-1), Merkel cell polyomavirus (MCV) and Helicobacter pylori.
- EBV Epstein-Barr virus
- HPV Human papillomavirus
- HBV Hepatitis B virus
- HCV Hepatitis C virus
- HHV8 Human Herpes virus 8
- HTLV-1 human T-cell leukemia virus type 1
- Merkel cell polyomavirus MCV
- Helicobacter pylori Helicobacter py
- prevention/treatment of a cancer is the stabilization of an already diagnosed cancer in an individual.
- stabilization it is meant the prevention of evolution of cancer into advanced or metastatic stage in patients with early stage cancer.
- mammals contemplated by the present invention include human, primates, domesticated animals such as cattle, sheep, pigs, horses, laboratory rodents and the like.
- the term “effective amount” as used herein refers to an amount of at least one polypeptide, cells loaded with said polypeptide, composition or pharmaceutical formulation thereof according to the invention, that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought.
- the effective amount is a “therapeutically effective amount” for the alleviation of the symptoms of the disease or condition being treated.
- the effective amount is a “prophylactically effective amount” for prophylaxis of the symptoms of the disease or condition being prevented.
- the term also includes herein the amount of active polypeptide sufficient to reduce the progression of the disease, notably to reduce or inhibit the tumor growth or infection and thereby elicit the response being sought (i.e. an “inhibition effective amount”).
- efficacy of a treatment according to the invention can be measured based on changes in the course of disease in response to a use or a method according to the invention.
- the efficacy of a treatment of cancer can be measured by a reduction of tumor volume, and/or an increase of progression free survival time, and/or a decreased risk of relapse post-resection for primary cancer.
- assessment of efficacy can be by the spectrum of clinical patterns of antitumor response for immunotherapeutic agents through novel immune-related response criteria (irRC), which are adapted from Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) criteria ( J. Natl. Cancer Inst. 2010, 102(18): 1388-1397).
- the efficacy of prevention of infectious disease is ultimately assessed by epidemiological studies in human populations, which often correlates with titres of neutralizing antibodies in sera, and induction of multifunctional pathogen specific T cell responses.
- Preclinical assessment can include resistance to infection after challenge with infectious pathogen.
- Treatment of an infectious disease can be measured by inhibition of the pathogen's growth or elimination of the pathogen (and, thus, absence of detection of the pathogen), correlating with pathogen specific antibodies and/or T cell immune responses.
- pharmaceutical formulation refers to preparations which are in such a form as to permit biological activity of the active ingredient(s) to be unequivocally effective and which contain no additional component which would be toxic to subjects to which the said formulation would be administered.
- an isolated polypeptide comprising:
- ZEBRA covers the basic-leucine zipper (bZIP) transcriptional activator of the Epstein-Barr virus (EBV), as well as a truncated form thereof retaining the capacity of internalization, such as the ZEBRA fragment comprising or consisting of amino acid sequence SEQ ID NO: 8, or any peptide with an identical or similar amino acid sequence, provided said ZEBRA fragment or identical or similar peptide retains the capacity of internalization of the protein comprising it.
- bZIP basic-leucine zipper
- EBV Epstein-Barr virus
- fusion protein of the invention comprising ZEBRA or ZEBRA fragment
- standard methods known to one skilled in the art including flow cytometry or fluorescence microscopy of live and fixed cells, immunocytochemistry of cells transduced with said fusion protein, and Western blot.
- the polypeptide of the invention comprises a ZEBRA fragment comprising or consisting of SEQ ID NO: 8 or any peptide having at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with SEQ ID NO: 8.
- the percentage of identity between two amino acid sequences or two nucleic acid sequences can be determined by visual inspection and/or mathematical calculation, or more easily by comparing sequence information using a computer program such as Clustal package version 1.83.
- the ZEBRA protein or fragment thereof that is comprised in the polypeptide of the invention comprises an amino acid sequence having at least one conservatively substituted amino acid from the native sequence, meaning that a given amino acid residue is replaced by a residue having similar physiochemical characteristics.
- substitutions for one or more amino acids present in the native amino acid sequence should be made conservatively.
- conservative substitutions include substitution of one aliphatic residue for another, such as Ile, VaI, Leu, or Ala for one another, or substitutions of one polar residue for another, such as between Lys and Arg; Glu and Asp; or Gln and Asn.
- Other such conservative substitutions for example, substitutions of entire regions having similar hydrophobicity properties, are well known (Kyte and Doolittle, 1982 , J. Mol. Biol. 157(1): 105-132).
- the CD4 + epitope(s) comprised in the polypeptide of the invention correspond(s) to antigenic determinant(s) of a tumor-associated antigen, a tumor-specific antigen, or an antigenic protein from a pathogen.
- the CD4 + epitopes comprised in the polypeptide of the invention generally, and preferably, consist of about 12-25 amino acids. They can also consist of about 8-25 amino acids or about 6-100 amino acids.
- the CD8 + epitope(s) comprised in the polypeptide of the invention correspond(s) to antigenic determinant(s) of an antigen such as a tumor-associated antigen, a tumor-specific antigen, or an antigenic protein from a pathogen.
- the CD8 + epitopes comprised in the polypeptide of the invention generally, and preferably, consist of about 8-11 amino acids. They may also consist of about 8-15 amino acids or about 6-100 amino acids.
- each of the epitopes comprised in the polypeptide of the invention can be either directly linked to each other or linked via spacers consisting of a few amino acids present between two successive epitopes.
- two successive epitopes comprised in the polypeptide of the invention are linked to each other by spacers consisting of the natural flanking regions of said epitopes.
- the spacer used to link a first epitope to a second epitope consists of about 8 amino acids corresponding to about 4 amino acids of the flanking region of the first epitope, followed by about 4 amino acids of the flanking region of the second epitope.
- the CD4 + and CD8 + epitopes are antigenic determinants from a tumor-associated antigen or a tumor-specific antigen.
- Exemplary tumor-associated antigens may be selected from the group of Melan A, MART-1, melanoma antigen family (MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A9, MAGE-A10, MAGE-A12, MAGE-C1, MAGE-C2), cancer/testis antigen family (LAGE-1, LAGE2), synovial sarcoma X breakpoint 2 (SSX-2), synovial sarcoma X breakpoint 4 (SSX-4), Transient axonal glycoprotein family (TAG-1, TAG-2, TAG-72), Taxol-resistant-associated gene 3 (TRAG-3), gp100, gp75, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2/glioblastoma oncogene homolog (HER-2/neu), prostate specific antigen (PSA), mucin 1(MUC-1), mucin 16 (CA-125),
- any epitope of any cancer- or tumor-associated antigen may be used.
- any epitope of any tumor-specific antigen may be used.
- tumor-associated antigens examples include tumor-associated antigens, tumor-specific antigens, and epitopes thereof, which can be comprised in the polypeptides of the invention are disclosed in Tables 1-4. This list is not limitative. Underlined are HLA alleles of MHC class II.
- Antigen alleles epitopes Ubiquitous (low enhancer of zeste A2 FMVEDETVL (SEQ ID NO: level) homolog 2 (EZH-2) A2 193) A24 FINDEIFVEL (SEQ ID NO: 194)
- A24 KYDCFLHPF SEQ ID NO: 195)
- KYVGIEREM SEQ ID NO: 196)
- Ubiquitous low v-erb-b2 erythroblastic A2 KIFGSLAFL (SEQ ID NO: 197) level) leukemia viral oncogene A2 IISAVVGIL (SEQ ID NO: 198) homolog 2,
- A2 ALCRWGLLL SEQ ID NO: neuro/glioblastoma A2 199) derived oncogene A2 ILHNGAYSL (SEQ ID NO: 200) homolog (HER-2/neu
- the CD4 + and CD8 + epitopes are antigenic determinants from a pathogen antigenic protein.
- viral antigens can be selected from the group consisting of viral meningitis, tuberculosis, encephalitis, dengue or smallpox, or it can be an antigen of a virus selected from the group consisting of smallpox virus, hepatitis type A, hepatitis type B, hepatitis type C, influenza, varicella, adenovirus, herpes simplex type I (HSV-I), herpes simplex type U (HSV-II), rinderpest, rhinovirus, echovirus, rotavirus, respiratory syncytial virus, human papilloma virus (including HPV 16 and HPV 18), papova virus, cytomegalovirus, echinovirus, arbovirus, huntavirus, coxsackie virus, mumps virus, measles virus, rubella virus, polio virus, human immunodeficiency virus (HIV), human immunodeficiency virus type I (HIV-I), human immunodefic
- bacterial antigens can be selected from the group consisting of antigens of Helicobacter pylori, Chlamydia pneumoniae, Chlamydia trachomatis, Ureaplasma urealyticum, Mycoplasma pneumoniae, Staphylococcus spp., Staphylococcus aureus, Streptococcus spp., Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus viridans, Enterococcus faecalis, Neisseria meningitidis, Neisseria gonorrhoeae, Bacillus anthracis, Salmonella spp., Salmonella typhi, Vibrio cholera, Pasteurella pestis, Pseudomonas aeruginosa, Campylobacter spp., Campylobacter jejuni, Clostridium spp., Clostridium difficile, Mycobacter
- protozoal antigens can be selected from the group consisting of antigens of leishmania, kokzidioa , and trypanosoma .
- polypeptide of the invention comprises at least two CD4 + epitopes and/or at least two CD8 + epitopes.
- the epitopes that are presented to CD8 + T cells are bound to highly polymorphic MHC class I molecules, specifically the alleles of HLA-A (>400 alleles), HLA-B (>700 alleles), and HLA-C(>200 alleles).
- the polymorphic MHC class II isotypes responsible for binding peptides recognized by CD4 + T cells are HLA-DR (DRA 3 alleles, DRB>500 alleles), HLA-DP (DPA>20 alleles, DPB>100 allotypes) and HLA-DQ (DQA>30 alleles, DQB>60 alleles).
- the polypeptides of the invention comprise multiple epitopes restricted by multiple MHC class I or class II molecules of said population.
- CD4 + epitopes are comprised in the polypeptide of the invention, said CD4 + epitopes are restricted by at least two MHC class II molecules of the patient population.
- CD8 + epitopes are comprised in the polypeptide of the invention, said CD8 + epitopes are restricted by at least two MHC class I molecules of the patient population.
- CD4 + epitopes and two or more CD8 + epitopes are comprised in the polypeptides of the invention, said CD4 + epitopes are restricted by at least two MHC class II molecules and said CD8 + epitopes are restricted by at least two MHC class I molecules of the patient population.
- the polypeptide of the invention comprises about 10 epitopes, or any number comprised between 10 to 100 epitopes, preferably 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, 60, 70, 80, 90 or 100 epitopes.
- an isolated polynucleotide encoding a polypeptide comprising:
- the protein transduction domain comprises a nucleotide sequence having at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with SEQ ID NO: 7.
- the protein transduction domain comprises or consists of the nucleotide sequence SEQ ID NO: 7.
- a recombinant vector comprising a polynucleotide according to the invention.
- chromosomes chromosomes
- episomes derived viruses
- the recombinant vectors used can be derived from bacterial plasmids, transposons, yeast episomes, insertion elements, yeast chromosome elements, viruses such as baculovirus, papilloma viruses such as SV40, vaccinia viruses, adenoviruses, fox pox viruses, pseudorabies viruses, retroviruses.
- recombinant vectors can equally be cosmid or phagemid derivatives.
- the nucleotide sequence can be inserted in the recombinant expression vector by methods well known to a person skilled in the art such as, for example, those that are described in MOLECULAR CLONING: A LABORATORY MANUAL, Sambrook et al., 4th Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y., 2001.
- the recombinant vector can include nucleotide sequences that control the regulation of the polynucleotide expression as well as nucleotide sequences permitting the expression and the transcription of a polynucleotide of the invention and the translation of a polypeptide of the invention, these sequences being selected according to the host cells that are used.
- an appropriate secretion signal can be integrated in the recombinant vector so that the polypeptide, encoded by the polynucleotide of the invention, will be directed towards the lumen of the endoplasmic reticulum, towards the periplasmic space, on the membrane or towards the extracellular environment.
- the choice of an appropriate secretion signal may facilitate subsequent protein purification.
- a host cell comprising a recombinant vector according to the invention.
- the introduction of the recombinant vector in a host cell can be carried out according to methods that are well known to a person skilled in the art, such as those described in BASIC METHODS IN MOLECULAR BIOLOGY, Davis et al., 2nd ed., McGraw-Hill Professional Publishing, 1995, and MOLECULAR CLONING: A LABORATORY MANUAL, supra, such as transfection by calcium phosphate, transfection by DEAE dextran, transfection, microinjection, transfection by cationic lipids, electroporation, transduction or infection.
- the host cell can be, for example, bacterial cells such as E. coli , cells of fungi such as yeast cells and cells of Aspergillus, Streptomyces , insect cells, Chinese Hamster Ovary cells (CHO), C127 mouse cell line, BHK cell line of Syrian hamster cells, Human Embryonic Kidney 293 (HEK 293) cells.
- the host cells can be used, for example, to express a polypeptide of the invention. After purification by standard methods, the polypeptide of the invention can be used in a method described hereinafter.
- antigen-presenting cells loaded with the polypeptides of the invention.
- the antigen presenting cells are selected among dendritic cells, macrophages and B-cells.
- Dendritic cells in particular dendritic cells (conventional and plasmacytoid) from the patient to be treated, are preferred.
- antigen-presenting cells in particular dendritic cells
- methods to extract antigen-presenting cells, in particular dendritic cells, from the patient are known to the skilled person. They include harvesting monocytes or hematopoietic stem cells from bone marrow, cord blood, or peripheral blood. They also include the use of embryonic stem (ES) cells and induced pluripotent stem cells (iPS).
- ES embryonic stem
- iPS induced pluripotent stem cells
- Antigen presenting cells, in particular dendritic cells or their precursors can be enriched by methods including elutriation and magnetic bead based separation, which may involve enrichment for CD14 + precursor cells.
- dendritic cells Preparation of dendritic cells can include their culture or differentiation using cytokines that may include GM-CSF and IL-4. Dendritic cell lines may also be employed. Loading of the polypeptide of the invention to the dendritic cells can involve co-incubation of the polypeptide of the invention with the cells in culture, making use of the intrinsic properties of the invention (i.e. the protein transduction domain). Further culture of the dendritic cells thus loaded to induce efficient maturation can include addition of cytokines including IL-1 ⁇ , IL-6, TNF ⁇ , PGE2, IFN ⁇ , and adjuvants which may include poly-IC.
- cytokines including IL-1 ⁇ , IL-6, TNF ⁇ , PGE2, IFN ⁇ , and adjuvants which may include poly-IC.
- the invention provides pharmaceutical compositions, in particular vaccine compositions, and methods for treating a subject, preferably a mammalian subject, and most preferably a human patient who is suffering from a medical disorder, and in particular a disorder that can be treated by immunotherapy such as cancers, infectious diseases, autoimmunity disorders and transplant rejections.
- compositions in particular vaccine compositions, or formulations according to the invention may be administered as a pharmaceutical formulation which can contain a polypeptide according to the invention in any form described herein.
- compositions in particular vaccine compositions, or formulations according to the invention may also be administered as a pharmaceutical formulation which can contain antigen presenting cells loaded with a polypeptide according to the invention in any form described herein.
- compositions according to the invention together with a conventionally employed adjuvant, carrier, diluent or excipient may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, or in the form of sterile injectable solutions for parenteral (including subcutaneous and intradermal) use by injection or continuous infusion.
- injectable compositions are typically based upon injectable sterile saline or phosphate-buffered saline or other injectable carriers known in the art.
- Such pharmaceutical compositions and unit dosage forms thereof may comprise ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
- suitable adjuvants include MPL® (Corixa), aluminum-based minerals including aluminum compounds (generically called Alum), ASO1-4, MF59, CalciumPhosphate, Liposomes, Iscom, polyinosinic:polycytidylic acid (polyIC), including its stabilized form poly-ICLC (Hiltonol), CpG oligodeoxynucleotides, Granulocyte-macrophage colony-stimulating factor (GM-CSF), lipopolysaccharide (LPS), Montanide, PLG, Flagellin, QS21, RC529, IC31, Imiquimod, Resiquimod, ISS, and Fibroblast-stimulating lipopeptide (FSL1).
- MPL® Corixa
- aluminum-based minerals including aluminum compounds (generically called Alum), ASO1-4, MF59, CalciumPhosphate, Liposomes, Iscom, polyinosinic:polycytidy
- compositions of the invention may be liquid formulations including, but not limited to, aqueous or oily suspensions, solutions, emulsions, syrups, and elixirs.
- the compositions may also be formulated as a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain additives including, but not limited to, suspending agents, emulsifying agents, non-aqueous vehicles and preservatives.
- Suspending agents include, but are not limited to, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminum stearate gel, and hydrogenated edible fats.
- Emulsifying agents include, but are not limited to, lecithin, sorbitan monooleate, and acacia.
- Preservatives include, but are not limited to, methyl or propyl p-hydroxybenzoate and sorbic acid.
- Dispersing or wetting agents include but are not limited to poly(ethylene glycol), glycerol, bovine serum albumin, Tween®, Span®.
- compositions of the invention may also be formulated as a depot preparation, which may be administered by implantation or by intramuscular injection.
- Solid compositions of this invention may be in the form of tablets or lozenges formulated in a conventional manner.
- tablets and capsules for oral administration may contain conventional excipients including, but not limited to, binding agents, fillers, lubricants, disintegrants and wetting agents.
- Binding agents include, but are not limited to, syrup, accacia, gelatin, sorbitol, tragacanth, mucilage of starch and polyvinylpyrrolidone.
- Fillers include, but are not limited to, lactose, sugar, microcrystalline cellulose, maizestarch, calcium phosphate, and sorbitol.
- Lubricants include, but are not limited to, magnesium stearate, stearic acid, talc, polyethylene glycol, and silica.
- Disintegrants include, but are not limited to, potato starch and sodium starch glycollate.
- Wetting agents include, but are not limited to, sodium lauryl sulfate. Tablets may be coated according to methods well known in the art.
- the compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems.
- compositions according to the invention are for subcutaneous use.
- compositions according to the invention are adapted for delivery by repeated administration.
- Another object of the invention is to provide a method of preparing a pharmaceutical composition according to the invention comprising the step of mixing a polypeptide according to the invention or antigen-presenting cells loaded with a polypeptide of the invention, and a pharmaceutically acceptable carrier.
- polypeptides according to the invention are useful in the prevention and/or treatment of a disease or a disorder, in particular those that can be treated or prevented by immunotherapy such as cancers and infectious diseases.
- Another object of the invention is a vaccination kit for treating, preventing or stabilizing a cancer or an infectious disease, comprising the pharmaceutical composition according to the invention and instructions for use of said pharmaceutical composition.
- a method for eliciting or improving, in a subject, an immunologic response against multiple epitopes that is dependent on CD4 + helper T cells and CD8 + cytotoxic T cells comprises administering a polypeptide of the invention to said subject.
- a method for eliciting or improving, in a subject, an immunologic response against multiple epitopes that is dependent on CD4 + helper T cells and CD8 + cytotoxic T cells comprises administering antigen-presenting cells loaded with a polypeptide of the invention to said subject.
- An immunologic response that is dependent on CD4 + and CD8 + response can be determined by evaluating an inflammatory response, a pro-inflammatory cytokine response, including an increase in the expression of one or more of IFN- ⁇ , TNF- ⁇ and IL-2 mRNA or protein relative to the level before administration of the compounds of the invention. It can also be measured by an increase in the frequency or absolute number of antigen-specific T cells after administration of the compounds of the invention, measured by HLA-peptide multimer staining, ELISPOT assays, and delayed type hypersensitivity tests. It can also be indirectly measured by an increase in antigen-specific serum antibodies that are dependent on antigen-specific T helper cells.
- a method for eliciting or improving, in a subject, an immunologic response against multiple epitopes that is restricted by multiple MHC class I molecules and multiple MHC class II molecules wherein said method comprises administering a polypeptide of the invention.
- a method for eliciting or improving, in a subject, an immunologic response against multiple epitopes that is restricted by multiple MHC class I molecules and multiple MHC class II molecules comprises administering antigen presenting cells of the invention to said subject.
- a method for eliciting or improving, in a subject, an immunologic response against multiple epitopes that is restricted by multiple MHC class I molecules and multiple MHC class II molecules can be determined by evaluating a cytokine response, including an increase in the expression of one or more of IFN- ⁇ , TNF- ⁇ and IL-2 mRNA or protein relative to the level before administration of the compounds of the invention, after in vitro stimulation of T cells with individual peptides binding to discrete MHC class I and class II molecules on antigen presenting cells. Restriction to different MHC molecules can also be validated by using antigen presenting cells expressing different MHC molecules, or by using MHC blocking antibodies. It can also be measured by an increase in the frequency or absolute number of antigen-specific T cells after administration of the compounds of the invention, measured by HLA-peptide multimer staining, which uses multimers assembled with discrete MHC molecules.
- the immune response is directed against multiple epitopes of a tumor-associated antigen or a tumor-specific antigen.
- the immune response is directed against multiple epitopes of an antigenic protein from a pathogen.
- Another embodiment of the invention provides the use of a polypeptide of the invention or the use of antigen-presenting cells loaded with a polypeptide of the invention for the preparation of a medicament for the prevention, treatment or stabilization of a disease or disorder, such as those which can be treated by immunotherapy, including cancers, infectious diseases, autoimmunity disorders and transplant rejections.
- the invention provides a method of preventing, treating or repressing a disease or disorder such as those which can be treated by immunotherapy, including cancers, infectious diseases, autoimmunity disorders and transplant rejections, wherein said method comprises administering a polypeptide of the invention, antigen presenting cells of the invention, or a pharmaceutical formulation thereof, to said subject.
- uses and methods of the invention comprises administration of a polypeptide according to the invention.
- Preferred cancers for the uses and methods of the invention include brain cancer, prostate cancer, breast cancer, ovarian cancer, esophageal cancer, lung cancer, liver cancer, kidney cancer, melanoma, gut carcinoma, lung carcinoma, head and neck squamous cell carcinoma, chronic myeloid leukemia, colorectal carcinoma, gastric carcinoma, endometrial carcinoma, myeloid leukemia, lung squamous cell carcinoma, acute lymphoblastic leukemia, acute myelogenous leukemia, bladder tumor, promyelocytic leukemia, non-small cell lung carcinoma, sarcoma.
- the cancer may be a solid tumor, blood cancer, or lymphatic cancer.
- the cancer may be benign or metastatic.
- More preferred cancers are brain tumors, in particular gliomas including glioblastoma multiforme (GBM).
- GBM glioblastoma multiforme
- Preferred infectious diseases for the uses and methods of the invention include diseases caused by viruses, bacteria, fungi, protozoa and multicellular parasites. They include, for instance, Amoebiasis, Anthrax, Buruli Ulcer ( Mycobacterium ulcerans ), Caliciviruses associated diarrhoea, Campylobacter diarrhoea, Cervical Cancer (Human papillomavirus), Chlamydia trachomatis associated genital diseases, Cholera, Crimean-Congo haemorrhagic fever, Dengue Fever, Diphtheria, Ebola haemorrhagic fever, Enterotoxigenic Escherichia coli (ETEC) diarrhoea, Gastric Cancer ( Helicobacter pylori ), Gonorrhea, Group A Streptococcus associated diseases, Group B Streptococcus associated diseases, Haemophilus influenzae B pneumonia and invasive disease, Hepatitis A, Hepati
- the antigen presenting cells are dendritic cells, more preferably dendritic cells from the subject to be treated.
- the therapeutically effective dose of a polypeptide according to the invention is from about 0.1 mg to 2 mg per injection.
- the therapeutically effective dose of an antigen presenting cell loaded with a polypeptide according to the invention is from about 0.2 million cells to 2 million cells per injection.
- the dosage administered, as single or multiple doses, to an individual will vary depending upon a variety of factors, including pharmacokinetic properties, patient conditions and characteristics (sex, age, body weight, health, size), extent of symptoms, concurrent treatments, frequency of treatment and the effect desired.
- compositions, in particular vaccine compositions, and formulations thereof according to this invention may be administered in any manner including orally, parenterally, intravenously, rectally, or combinations thereof.
- Parenteral administration includes, but is not limited to, intravenous, intra-arterial, intra-peritoneal, subcutaneous, intradermal and intramuscular.
- the compositions of this invention may also be administered in the form of an implant, which allows slow release of the compositions as well as a slow controlled i.v. infusion.
- the compounds, compositions, in particular vaccine compositions, and formulations thereof according to the invention are administered subcutaneously.
- the administration of the polypeptides, antigen presenting cells and compositions of the invention requires multiple successive injections.
- the administration can be repeated at least two times, once as primary immunization injections and, later, as booster injections.
- the vaccine composition may be administered repeatedly or continuously.
- the vaccine composition can be administered repeatedly or continuously for a period of at least 1, 2, 3, or 4 weeks; 2, 3, 4, 5, 6, 8, 10, or 12 months; or 2, 3, 4, or 5 years.
- the administration of the pharmaceutical compositions in the methods and uses according to the invention can be carried out alone or in combination with a co-agent useful for treating and/or stabilizing the disease or disorder to be treated or repressed.
- a co-agent useful for treating and/or stabilizing the disease or disorder to be treated or repressed In the case of treatment, prevention, or stabilization of a cancer, the administration of the pharmaceutical compositions in the methods and uses according to the invention can be carried out in combination with substances used in conventional chemotherapy directed against solid tumors and for control of establishment of metastases or any other molecule that act by triggering programmed cell death e.g.
- the administration of the pharmaceutical compositions in the methods and uses according to the invention can be carried out in parallel of radiotherapy.
- the invention encompasses the administration of a polypeptide of the invention, or an antigen-presenting cell of the invention, or a pharmaceutical composition thereof according to the invention, wherein it is administered to a subject prior to, simultaneously or sequentially with other therapeutic regimens or co-agents useful for treating, and/or stabilizing a cancer and/or preventing cancer relapsing (e.g. multiple drug regimens), in a therapeutically effective amount.
- a polypeptide of the invention, or an antigen-presenting cell of the invention, or a pharmaceutical composition thereof according to the invention that is administered simultaneously with said co-agents can be administered in the same or different composition(s) and by the same or different route(s) of administration.
- Said other therapeutic regimens or co-agents may be selected from the group consisting of radiation therapy, chemotherapy, surgery, targeted therapy (including small molecules, peptides and monoclonal antibodies), and anti-angiogenic therapy.
- Anti-angiogenic therapy is defined herein as the administration of an agent that directly or indirectly targets tumor-associated vasculature.
- a pharmaceutical formulation comprising a polypeptide of the invention or an antigen-presenting cell of the invention, combined with at least one co-agent useful for treating and/or stabilizing a cancer and/or preventing a cancer relapsing, and at least one pharmaceutically acceptable carrier.
- the compounds according to the invention and pharmaceutical formulations thereof can be administered after surgery where solid tumors have been removed as a prophylaxis against relapsing and/or metastases.
- patients according to the invention are patients suffering from a cancer.
- patients according to the invention have been subjected to a chirurgical removal of a tumor.
- patients according to the invention are patients suffering from an infectious disease.
- FIG. 1 Three different constructs ( FIG. 1 ) were engineered and cloned in a modified pET-15b vector deleted for thrombin and stop codons.
- N-terminal fusion proteins comprising amino acids residues 178-220 of ZEBRA (NCBI Accession Number YP — 401673) were made carrying His-Tag allowing protein purification.
- the amino acid sequence of the ZEBRA fragment comprised in the ZEBRA fusion proteins described in the examples is SEQ ID NO: 8.
- Construct 1 ZEBRA- ⁇ -lactamase: encodes ⁇ -lactamase from E. Coli deleted for the secretion signal (residues 1-23) and residue 24 His was changed to Asp to create an optimal Kozak sequence.
- Construct 2 ZEBRA-OVA: encodes a truncated form of the chicken ovalbumin (OVA 234-386 ). This construction contains both CD8 epitope OVA 257-264 and CD4 epitope OVA 323-339 .
- Construct 3 ZEBRA-MultiE: encodes a chimeric protein with three CD8 epitopes from the ovalbumin OVA 257-2645 from lymphocytic choriomengitis virus glycoprotein LCMV-GP 33-41 and from the murine tumor-associated antigen GP100 25-33 and two CD4 epitopes: OVA 323-339 and LCMV-GP 61-80 .
- the spacers between each epitope are the natural flanking 4 amino acids residues.
- CCF2-AM is a lipophilic and esterified substrate, which can enter into the cells. Endogenous cytoplasmic esterase rapidly converts CCF2-AM into a negatively charged form (CCF2), which is not able to cross cell membranes, including endosomal membranes. Therefore, the ⁇ -lactamase transduced into cells with ZEBRA (construct 1) can cleave the CCF2 that is free in the cytoplasm.
- TCR transgenic mice have all the CD8 + or CD4 + T cells specific for one epitope.
- the CD8 + TCR transgenic mice used here are OT-1, specific for the OVA 257-264 epitope.
- Bone marrow derived dendritic cells were loaded with ZEBRA-OVA 257-264 during 4 h, washed and matured overnight with maturation cocktail containing IFN ⁇ , IFN ⁇ , IL-4 and PolyIC (Fujita et al., 2009, Cancer Res. 69:1587-1595).
- OT-1 cells were stained with the non-toxic dye carboxyfluorescein succinimidyl ester (CFSE). Cell proliferation results in dilution of CFSE, which can be monitored by flow cytometry.
- CFSE stained OT-1 cells were incubated with matured BMDCs at a ratio 10:1 during 5 day. As positive control, mature BMDCs were pulsed with 10 ⁇ M Ova peptide.
- OT-1 T cells were incubated without any stimulation.
- DCs loaded with ZEBRA-OVA 257-264 had the same priming capacity as peptide pulsed DCs with 81% and 93% proliferating CD8+ T cells, respectively.
- the same experiment was performed with BMDCs loaded with ZEBRA-OVA 257-264 after maturation.
- BMDCs loaded before or after maturation had the same priming capacity with 69% and 70% proliferating CD8+ respectively, confirming that cross-presentation results from ZEBRA-mediated antigen delivery.
- OVA-specific CD4 epitope (OVA 323-339 ) was monitored with the OT-2 TCR transgenic mice.
- DCs loaded with ZEBRA-OVA 257-264 were able to activate OVA-specific CD4 + T-cells.
- a chimeric protein (called ZEBRA-MultiE fusion protein corresponding to construct 3) encoding OVA, the tumor-associated antigen gp100 and the viral LCMV-GP peptides was loaded into DCs and MHC I restricted presentation was monitored in vitro with lymphocytes from OT-1 mice, Pmel-1 mice transgenic for the gp100-specific TCR (GP100 25-33 ) and P14 mice transgenic for the LCMV-GP-specific TCR (LCMV-GP 33-41 ), respectively. MHC II restricted presentation was also monitored with lymphocytes from OT-2 mice and SMARTA mice transgenic for the LCMV-GP-specific TCR (LCMV-GP 61-80 ).
- Multi-epitopic presentation was observed with 3 CD8 + epitopes ( FIGS. 2 ) and 2 CD4 + ( FIG. 3 ) epitopes being efficiently presented.
- the presentation of gp100 was low, but significant. This may reflect the low affinity interaction of murine gp100 with the murine MHC class I molecule H-2D b .
- the percentage of proliferating T cells after priming with DC loaded with ZEBRA-MultiE is similar to peptide pulsed DCs.
- T cell activation through engagement of the T cell receptor (TCR) with the epitope-MHC complex.
- TCR T cell receptor
- full differentiation to functional T cells includes expression of cytokines including IFN ⁇ , TNF ⁇ and some IL-2.
- CD4 Th cells can polarize into Th1 (IFN ⁇ + IL-2 + TNF ⁇ + ) promoting cell-mediated immune responses, or Th2 (IL-4 + ) promoting antibody mediated immune response.
- the goal here was to assess the cytokine profiles of CD8 + and CD4 + T cells activated in vitro. The supernatant was analyzed after 5 days of culture ( FIG. 4 ).
- CD8 + T cells primed with BMDCs loaded with ZEBRA-MultiE were producing IFN ⁇ and TNF ⁇ as the same level as the CD8 + T cells primed with peptide pulsed DCs ( FIG. 4 ).
- No IL-2 was found in the culture supernatant of CD8+ T cells cultivated with ZEBRA-MultiE loaded BMDCs.
- CD4+ T cells showed a Th1 polarization with secretion of IFN ⁇ and TNF ⁇ , and again no IL-2 was found.
- ZEBRA-MultiE transduced DC The potential of ZEBRA to deliver antigens in vivo was then evaluated by either vaccinating with ZEBRA-MultiE transduced DC, or directly with the ZEBRA-MultiE fusion protein.
- mice were vaccinated twice with a 14-days interval with type 1 polarized (Fujita et al., 2009, Cancer Res. 69:1587-1595) BMDC (10 6 mature DCs per vaccination) loaded with ZEBRA-MultiE. Seven days after the second vaccination, cells were isolated from lymph node and spleen, restimulated with the peptides contained in MultiE, and intracellular cytokine expression was measured in both CD4 and CD8 T cell populations ( FIG. 5 ). The proportion of CD8 + (top panel) or CD4 + (bottom panel) T cells expressing each cytokine after in vitro restimulation with each peptide epitope is plotted in the bar chart.
- the multifunctionality of the response (capacity to express 1, 2, or 3 cytokines) is illustrated in the pie chart. Some multifunctionality ( ⁇ 2 cytokines) is present for every epitope tested, although the proportions of multifunctional T cells vary according to the epitope.
- mice were vaccinated subcutaneously twice with a 14-days interval with 6 ⁇ g ZEBRA-MultiE and 100 ⁇ g PolyIC. Seven days after the second vaccination, cells were isolated from lymph node and spleen, restimulated with the peptides contained in ZEBRA-MultiE, and intracellular cytokine expression was measured in both CD4 and CD8 T cell populations ( FIG. 6 ). The proportion of CD8 + (top panel) or CD4 + (bottom panel) T cells expressing each cytokine after in vitro restimulation with each peptide epitope is plotted in the bar chart. The multifunctionality of the response (capacity to express 1, 2, or 3 cytokines) is illustrated in the pie chart.
- the MHC restriction elements for each epitope are: OVA 257-264 : H-2Kb; OVA 323-339 : H-2-I-Ab; LCMV-GP 33-41 :H-2Db; gp100 25-33 :H-2Db; LCMV-GP 61-80 :H-2-IAb).
- Zebra-Multie can be Processed and Presented by Dendritic Cells with Different MHC Molecules
- Bone marrow derived dendritic cells from mice on BALB/c background were loaded for 4 h with 0.3 ⁇ M Zebra-MultiE and matured overnight with poly ICLC (Hiltonol®).
- Zebra-MultiE loaded and matured dendritic cells were co-incubated with CFSE stained splenocytes from DO11.10 TCR transgenic mice in which all of the CD4 + T cells are specific for the immunodominant ovalbumin epitope OVA 257-264 .
- As negative control splenocytes were incubated with non-loaded dendritic cells.
- the dendritic cells were pulsed with peptide. After five days of culture, T cell proliferation by CFSE dilution was monitored by flow cytometry.
- Results of FIG. 7 show that Zebra-MultiE can be processed and presented by dendritic cells with different MHC molecules.
- C57BL/6 mice were vaccinated with PBS for the negative control, 200 ⁇ g peptides and 100 ⁇ g anti-CD40 subcutaneously and 50 ⁇ g Poly ICLC (Hiltonol®) intramuscularly for the positive control or 10 ⁇ g ZEBRA-MultiE protein and 100 ⁇ g anti-CD40 subcutaneously and 50 ⁇ g Poly ICLC (Hiltonol®) intramuscularly.
- the same day 1.5 ⁇ 10 6 CFSE stained splenocytes from either P14 or OT1 TCR transgenic mice were adoptively transferred by intravenous injection. Four days after vaccination/adoptive transfer, the mice were sacrificed and proliferation of adoptively transferred T cell from draining lymph nodes was assessed by CFSE dilution.
- Results of FIG. 8 show that Zebra-MultiE translocates into endogenous dendritic cells in vivo and is processed, leading to cross-presentation on MHC class I molecules.
- mice were vaccinated twice at 14-days of interval by subcutaneous injection of 10 ⁇ g ZEBRA-MultiE protein and 100 ⁇ g anti-CD40 and intramuscular injection of 50 ⁇ g Poly ICLC (Hiltonol®). Seven days after the boost, the mice were sacrificed and the percentages of CD8 + T cells specific for either OVA 323-339 , LCMV-GP 33-41 , or GP100 25-33 were assessed in the draining lymph nodes by tetramer staining.
- FIG. 9 show that vaccination of mouse with ZEBRA-MultiE can induce polyclonal immune responses.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- This application is a continuation of U.S. Ser. No. 13/415,877, filed Mar. 9, 2012, which claims the benefit of U.S. Provisional Patent Application 61/451,615, filed Mar. 11, 2011, the disclosure of which is hereby incorporated by reference in its entirety, including all figures, tables, amino acid sequences and polynucleotide sequences.
- The Sequence Listing for this application is labeled “Seq-List.txt” which was created on May 25, 2014 and is 73 KB. The entire contents of the sequence listing is incorporated herein by reference in its entirety.
- The present invention relates to a multi-epitopic vaccine and its use in immunotherapy including prevention and/or treatment of cancers or infectious diseases.
- Immunotherapy is gaining importance for the treatment and prevention of various human diseases, including infectious diseases and cancers.
- Regarding immunotherapy in cancers, with the recent FDA approval of the Sipuleucel-T vaccine for prostate cancer, the feasibility of active immunization for the treatment of established cancer has been demonstrated.
- It is now established that the immune system can recognize and to some extent eliminate tumor cells through different cells subsets including CD8 cytotoxic T lymphocytes (CTLs). Modulating the immune system in order to track and specifically destroy the tumor cells is a promising therapeutic approach (also called anti-tumoral immunotherapy) for treating patients.
- Tumor-associated antigens recognized by CTLs are 8 to 11 residue peptides called CD8+ epitopes which are bound to MHC class I molecules and displayed at the tumor cell surface. In the last decade, an increasing number of these peptides derived from the processing of tumor proteins have been identified and classified as tumor specific antigens (TSA) or tumor-associated antigens (TAAs). The main goal of current research on immunotherapy approaches is to elicit potent anti-tumor immunity after therapeutic vaccination against these antigens. Approaches widely developed and transferred to clinical trials include peptide vaccination and adoptive immunotherapy with ex-vivo loaded dendritic cells (DCs).
- However, the clinical successes of these approaches have been modest. Among other reasons, this failure can be explained both by the very immunosuppressive properties of the tumor microenvironment and by the different immune escape mechanisms developed by the tumor cells including the loss of individual antigens.
- Recently, the key role of another subset of T cells, called CD4+ helper T cells (Th), has been described in anti-tumor immunity. Indeed, it has been reported that this CD4 compartment plays a crucial role in mounting an efficient anti-tumoral immune response (Bos and Sherman, 2010, Cancer Res. 70:8368-8377). As for CD8 T cells, Th cells are also involved in the maintenance of long-lasting cellular immunity (immunological memory), and tumor infiltration by Th cells is an essential step for the recruitment and function of CTLs.
- Tumor-associated antigens recognized by Th cells are typically 12-25 residue peptides (although some are much longer) called CD4+ epitopes which are bound to MHC class II molecules and displayed at the tumor cell surface.
- The use of protein rather than peptides to induce anti-tumor immunity would allow multi-epitopic (CD8+ and CD4+ epitopes) antigen delivery to antigen presenting cells (APCs) such as dendritic cells (DCs). However, protein uptake by APCs is limited and frequently results in presentation of only CD4 epitopes by MHC class II molecules. This is because protein antigens taken up from the extracellular milieu do not efficiently enter the cytoplasm from where their constituent peptide epitopes can bind to MHC class I molecules being assembled in the endoplasmic reticulum (a process called cross-presentation). Therefore, there is a need to develop new approaches to increase the efficiency of protein uptake by DCs, and to facilitate presentation of both CD4 and CD8 epitopes.
- Different vectors have been developed and evaluated to deliver different MHC class I restricted epitopes; these include viral vectors (Durantez et al., 2009, Scand. J. Immunol 69:80-89; Mateo et al., 1999, J. Immunol. 163:4058-4063; Tine et al., 2005, Vaccine 23:1085-1091), cDNA-based vaccine (Ishioka et al., 1999, J. Immunol. 162:3915-3925; Scardino et al., 2007, Cancer Res. 67:7028-7036) and mRNA electroporated dendritic cells (Waeckerle-Men et al., 2006, Cancer Immunol. Immunother. 55:1524-1533).
- In addition to minimizing immune escape, targeting multiple epitopes allows a greater proportion of tumor cells in a heterogenous tumor (i.e. different individual tumor cells expressing different antigens within same tumor) to be attacked. Some progress has been made for vaccinia virus vectors encoding multiple epitopes associated with infectious diseases (Thomson et al., 1996, J. Immunol. 157:822-826; Thomson et al., 1995, Proc. Natl. Acad. Sci.
- USA. 92:5845-5849; Anton et al., 1997, J. Immunol. 158:2535-2542). However, several limitations have been noted. The first is that vaccinia virus vectors encoded antigens are preferentially presented by MHC class I restricted molecules; second, there is a limitation of the size of insert; third, there is rapid degradation of the encoded antigens, and finally there are many regulatory hurdles for clinical translation.
- An alternative approach that has several inherent advantages is a multi-epitope vaccine based on protein rather than on a viral or DNA based vaccine. This offers the major advantage of long-lasting MHC presentation of the cargo antigens to T lymphocytes (van Montfoort et al., 2009, Proc. Natl. Acad. Sci. USA. 106:6730-6735), but low immunogenicity of the vector-allowing for multiple vaccinations.
- In the past decade, protein transduction domains (PTDs) are emerging as promising vectors to deliver different therapeutic targets, including proteins. PTDs are peptide sequences facilitating efficient protein translocation across biological membranes, independently of transporters or specific receptors. PTDs also offer the advantage of cost-efficient production. Since the discovery 20 years ago of the membrane translocating property of human immunodeficiency virus transactivating regulatory protein (HIV TAT), several PTDs have been identified including penetratin (Antennapedia homeodomain), VP22 (Herpes simplex virus) and the synthetic polyarginine (polyR). Different cargoes have been linked to PTD with the perspective of novel vaccine design. These include tumor-associated antigen for cancer immunotherapy.
- The most widely studied PTD, TAT, was fused to different antigens and used to transduce dendritic cells (in virtually all studies) before testing immunogenicity in vivo (Brooks et al., 2010, Biochimica et Biophysica Acta 1805:25-34). In all these studies, a CTL-mediated immune response (i.e. mediated by CD8 T cells and restricted by MHC class I) was demonstrated after loading the DCs with the TAT-fusion protein, in contrast to the protein alone, and in some cases, CD4 T cells were also implicated. Moreover, vaccination with TAT fused to TRP2 resulted in long-term protection as shown in tumor-free mice re-challenged with the tumor, suggesting a superior memory response. However, there are several potential drawbacks concerning TAT. The first is that the use of TAT based vaccines directly in vivo without prior transduction of DCs remains largely unexplored. The second is that the nature of the cargo transported into the cell by TAT influences intracellular localisation; large TAT-fusion proteins can remain entrapped in endosomes where they are degraded, which is predicted to limit access to the cross-presentation pathway resulting in poor stimulation of CD8 T cells (Tünnemann et al., 2006, FASEB J., 20: 1775-1784).
- Therefore, there is still a need for developing anti-tumor and anti-pathogen vaccines able to induce strong and broad T-cell responses specific for multiple epitopes of a given antigen, involving both CD4+ and CD8+ cells, preferably applicable to a broad range of patients, and that have the potential for direct injection into patients, without requiring DCs. The present invention solves this problem by providing a PTD fusion protein allowing efficient delivery and presentation of multiple CD4+- and CD8+-restricted epitopes. The multi-epitopic PTD fusion protein of the invention, thus, is useful in immunotherapy for treating and/or preventing cancers or infectious diseases.
- A first aspect of the invention provides an isolated polypeptide comprising:
-
- (i) a protein transduction domain consisting of ZEBRA or a fragment thereof that retains the capacity of internalization,
- (ii) at least one CD4+ epitope; and
- (iii) at least one CD8+ epitope.
- A second aspect of the invention provides an isolated polynucleotide encoding a polypeptide of the invention, a recombinant vector comprising said polynucleotide, as well as a host cell comprising said recombinant vector.
- A third aspect of the invention provides antigen presenting cells loaded with a polypeptide of the invention.
- A fourth aspect of the invention provides a vaccine composition comprising a polypeptide of the invention or antigen presenting cells of the invention, for preventing, treating, or stabilizing cancers or infectious diseases.
- A fifth aspect of the invention provides a use of a polypeptide of the invention or the use of antigen presenting cells loaded with a polypeptide of the invention in the manufacture of a medicament.
- A sixth aspect of the invention provides a method of preventing, treating or stabilizing a cancer or an infectious disease in a subject said method comprising administering in a subject in need thereof a therapeutically effective amount of a polypeptide of the invention or antigen presenting cells of the invention, and at least one pharmaceutically acceptable carrier.
- A seventh aspect of the invention provides a method for eliciting or improving, in a subject, an immunologic response against multiple epitopes that is dependent on CD4+ helper T cells and CD8+ cytotoxic T cells, wherein said method comprises administering either a polypeptide of the invention or antigen presenting cells of the invention to said subject.
- An eighth aspect of the invention provides a method for eliciting or improving, in a subject, an immunologic response against multiple epitopes that is restricted by multiple MHC class I molecules and multiple MHC class II molecules, wherein said method comprises administering either a polypeptide of the invention or antigen presenting cells of the invention to said subject.
-
FIG. 1 shows different ZEBRA-fusion proteins used in the experimental section. - Construct 1: ZEBRA-β-lactamase: encodes β-lactamase from E. Coli deleted for the secretion signal (residues 1-23) and residue 24 His was changed to Asp to create an optimal Kozak sequence.
- Construct 2: ZEBRA-OVA: encodes a truncated form of the chicken ovalbumin (OVA234-386). This construction contains both CD8 epitope OVA257-264 and CD4 epitope OVA323-339.
- Construct 3: ZEBRA-MultiE: encodes a chimeric protein with three CD8 epitopes from the ovalbumin OVA257-264, from lymphocytic choriomengitis virus glycoprotein LCMV-GP33-41 and from the murine tumor-associated antigen GP10025-33 and two CD4 epitopes: OVA323-339 and LCMV-GP61-80. The spacers between each epitope are the natural flanking 4 amino acid residues.
-
FIG. 2 shows CD8+ multi-epitopic presentation after ZEBRA-multiE fusion protein loading into DCs. - Bone marrow dendritic cells from C57BL/6 mice were loaded with 0.3 μM ZEBRA-MultiE during 4 h and matured overnight with a cocktail containing IFNα, IFNγ, IL-4 and PolyIC. CFSE stained CD8 T cells from either OT-1, Pmel or P14 mice were added at a ratio 10:1. After 5 days of proliferation, dilution of CFSE was monitored by flow cytometry.
-
FIG. 3 shows CD4+ multi-epitopic presentation after ZEBRA-multiE fusion protein loading into DCs. - Bone marrow dendritic cells from C57BL/6 mice were loaded with 0.3 μM ZEBRA-MultiE during 4 h and matured overnight with a cocktail containing IFNα, IFNγ, IL-4 and PolyIC. CFSE stained CD4 T cells from either OT-2 or SMARTA mice were added at a ratio 10:1. After 5 days of proliferation, dilution of CFSE was monitored by flow cytometry.
-
FIG. 4 shows effector function of T cells primed in vitro by DCs loaded with ZEBRA-MultiE fusion protein. - Bone marrow dendritic cells from C57BL/6 mice were loaded with 0.3 μM ZEBRA-MultiE during 4 h and matured overnight with a cocktail containing IFNα, IFNγ, IL-4 and PolyIC. CFSE stained CD8 T cells from either OT-1, Pmel or P14 mice and CD4 T cells from either OT-2 or SMARTA mice were added at a ratio 10:1. After 5 days of proliferation, the supernatant was tested for cytokine expression using the Multiplex cytokine detection kits (BD Biosciences Pharmingen, San Diego, Calif.) and analyzed by flow cytometry.
-
FIG. 5 shows the results of vaccination of mice with DCs loaded with ZEBRA-MultiE fusion protein. - C57BL/6 mice were vaccinated subcutaneously twice with a 14 days of interval with 1×106 mature dendritic cells loaded with ZEBRA-MultiE. 7 days after the last vaccination, splenocytes were recovered and re-stimulated during 7 days with 10 μM of the respective peptides. The T cells were re-stimulated with 10 μM of the respective peptide during 4 h and intracellular staining for IFNγ, TNFα and IL-2 was performed and analyzed by flow cytometry. Multi-functional analysis was performed with SPICE (Roeder et al, 2011, Cytometry, 79A:167-174). The figures show the percentage of positive cells gated on CD8+ or CD4+ T cells, respectively.
-
FIG. 6 shows the results of vaccination of mice with ZEBRA-MultiE fusion protein. - C57BL/6 mice were vaccinated subcutaneously twice with a 14 days of interval with 2×6 μg ZEBRA-MultiE and 100 μg PolyIC. 7 days after the last vaccination, splenocytes were recovered and re-stimulated during 7 days with 10 μM of the respective peptides. The T cells were re-stimulated with 10 μM of the respective peptide during 4 h and intracellular staining for IFNγ, TNFα and IL-2 was performed and analyzed by flow cytometry. Multi-functional analysis was performed with SPICE.
-
FIG. 7 shows that Zebra-MultiE can be processed and presented by dendritic cells with different MHC molecules. - Bone marrow derived dendritic cells from mice on BALB/c background were loaded for 4 h with 0.3 μM Zebra-MultiE and matured overnight with poly ICLC (Hiltonol®). Zebra-MultiE loaded and matured dendritic cells were co-incubated with CFSE stained splenocytes from DO11.10 TCR transgenic mice in which all of the CD4+ T cells are specific for the immunodominant ovalbumin epitope OVA257-264. Negative control: splenocytes were incubated with non-loaded dendritic cells. Positive control: dendritic cells were pulsed with peptide. After five days of culture, T cell proliferation by CFSE dilution was monitored by flow cytometry.
-
FIG. 8 shows that Zebra-MultiE translocates into endogenous dendritic cells in vivo, is processed leading to cross-presentation on MHC class I molecules. - C57BL/6 mice were vaccinated with PBS (negative control), 200 μg peptides and 100 μg anti-CD40 subcutaneously and 50 μg Poly ICLC (Hiltonol®) intramuscularly (positive control) or 10 μg ZEBRA-MultiE protein and 100 μg anti-CD40 subcutaneously and 50 μg Poly ICLC (Hiltonol®) intramuscularly. The same day, 1.5×106 CFSE stained splenocytes from either P14 or OT1 TCR transgenic mice were adoptively transferred by intravenous injection. Four days after vaccination/adoptive transfer, the mice were sacrificed and proliferation of adoptively transferred T cell from draining lymph nodes was assessed by CFSE dilution.
-
FIG. 9 shows that vaccination of mouse with ZEBRA-MultiE can induce polyclonal immune responses. - C57BL/6 mice were vaccinated twice at 14-days of interval by subcutaneous injection of 10 μg ZEBRA-MultiE protein and 100 μg anti-CD40 and intramuscular injection of 50 μg Poly ICLC (Hiltonol®). Seven days after the boost, the mice were sacrificed and the percentages of CD8+ T cells specific for either OVA323-339, LCMV-GP33-41, or GP10025-33 were assessed in the draining lymph nodes by tetramer staining.
- The term “ZEBRA” (also known as Zta, Z, EB1, or BZLF1) generally means the basic-leucine zipper (bZIP) transcriptional activator of the Epstein—Barr virus (EBV). It also includes, herewith, a truncated form thereof retaining the capacity for internalization, such as the minimal domain (MD) currently known as spanning from residue 170 to residue 220 of ZEBRA (Rothe et al., 2010, J. Biol. Chem. 285: 20224-20233), as well as any fragment of the minimal domain mentioned above such as a fragment comprising or consisting of amino acid sequence SEQ ID NO: 8, or any peptide with a similar amino acid sequence as ZEBRA or ZEBRA fragment, provided said fragment or similar peptide still retains the capacity of internalization. The amino acid sequence of ZEBRA is disclosed under NCBI accession number YP—401673.
- The term “epitope”, also known as “antigenic determinant”, is the part of an antigen that is recognized by the immune system, specifically by antibodies, B cells, or T cells. In the present application, the term “epitope” is mainly used to designate T cell epitopes, which are presented on the surface of an antigen-presenting cell, where they are bound to Major Histocompatibility Complex (MHC). T cell epitopes presented by MHC class I molecules are typically, but not exclusively, peptides between 8 and 11 amino acids in length, whereas MHC class II molecules present longer peptides, generally, but not exclusively, between 12 and 25 amino acids in length.
- The term “CD4 epitope” or “CD4+-restricted epitope” designates, herewith, an epitope recognized by a CD4 T cell, said epitope consisting of an antigen fragment lying in the groove of a MHC class II molecule.
- “CD8+ epitope” or “CD8+-restricted epitope” designates, herewith, an epitope recognized by a CD8+ T cell, said epitope consisting of an antigen fragment lying in the groove of a MHC class I molecule.
- “MHC class I” designates one of the two primary classes of the Major Histocompatibility Complex molecules. The MHC class I (also noted “MHC I”) molecules are found on every nucleated cell of the body. The function of MHC class I is to display an epitope to cytotoxic cells (CTLs). In humans, MHC class I molecules consist of two polypeptide chains, α- and β2-microglobulin (b2m). Only the α chain is polymorphic and encoded by a HLA gene, while the b2m subunit is not polymorphic and encoded by the Beta-2 microglobulin gene.
- “MHC class II” designates the other primary class of the Major Histocompatibility Complex molecules. The MHC class II (also noted “MHC II”) molecules are found only on a few specialized cell types, including macrophages, dendritic cells and B cells, all of which are professional antigen-presenting cells (APCs).
- “Tumor epitope” means, herewith, an epitope from a tumor-associated antigen or from a tumor-specific antigen. Examples of tumor-associated and tumor-specific epitopes are provided in Tables 1-4.
- “Pathogen epitope” means, herewith, an epitope from an antigenic protein from a pathogen including viruses, bacteria, fungi, protozoa and multicellular parasites. Antigenic proteins from pathogens include, herewith, proteins from pathogens responsible of diseases which can be a target for vaccination including, for instance, Amoebiasis, Anthrax, Buruli Ulcer (Mycobacterium ulcerans), Caliciviruses associated diarrhoea, Campylobacter diarrhoea, Cervical Cancer (Human papillomavirus), Chlamydia trachomatis associated genital diseases, Cholera, Crimean-Congo haemorrhagic fever, Dengue Fever, Diptheria, Ebola haemorrhagic fever, Enterotoxigenic Escherichia coli (ETEC) diarrhoea, Gastric Cancer (Helicobacter pylori), Gonorrhea, Group A Streptococcus associated diseases, Group B Streptococcus associated diseases, Haemophilus influenzae B pneumonia and invasive disease, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis E diarrhoea, Herpes simplex type 2 genital ulcers, HIV/AIDS, Hookworm Disease, Influenza, Japanese encephalitis, Lassa Fever, Leishmaniasis, Leptospirosi, Liver cancer (Hepatitis B), Liver Cancer (Hepatitis C), Lyme Disease, Malaria, Marburg haemorrhagic fever, Measles, Mumps, Nasopharyngeal cancer (Epstein-Barr virus), Neisseria meningitidis Meningitis, Parainfluenza associated pneumonia, Pertussis, Plague, Poliomyelitis, Rabies, Respiratory syncytial virus (RSV) pneumonia, Rift Valley fever, Rotavirus diarrhoea, Rubella, Schistosomiasis, Severe Acute Respiratory Syndrome (SARS), Shigellosis, Smallpox, Staphylococcus aureus associated diseases, Stomach Cancer (Helicobacter pylori), Streptococcus pneumoniae and invasive disease, Tetanus, Tick-borne encephalitis, Trachoma, Tuberculosis, Tularaemia, Typhoid fever, West-Nile virus associated disease, Yellow fever.
- As used herein, “treatment” and “treating” and the like generally mean obtaining a desired pharmacological and physiological effect. The effect may be prophylactic in terms of preventing or partially preventing a disease, symptom or condition thereof and/or may be therapeutic in terms of a partial or complete cure of a disease, condition, symptom or adverse effect attributed to the disease. The term “treatment” as used herein covers any treatment of a disease in a mammal, particularly a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it such as a preventive early asymptomatic intervention; (b) inhibiting the disease, i.e., arresting its development; or relieving the disease, i.e., causing regression of the disease and/or its symptoms or conditions such as improvement or remediation of damage. In particular, the methods, uses, formulations and compositions according to the invention are useful in the treatment of cancers or infectious diseases and/or in the prevention of evolution of cancers into an advanced or metastatic stage in patients with early stage cancer, thereby improving the staging of the cancer.
- When applied to cancers, prevention of a disease or disorder includes the prevention of the appearance or development of a cancer in an individual identified as at risk of developing said cancer, for instance due to past occurrence of said cancer in the circle of the individual's relatives, and prevention of infection with tumor promoting pathogens such as, for example, Epstein-Barr virus (EBV), Human papillomavirus (HPV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human Herpes virus 8 (HHV8), human T-cell leukemia virus type 1 (HTLV-1), Merkel cell polyomavirus (MCV) and Helicobacter pylori.
- Also covered by the terms “prevention/treatment” of a cancer is the stabilization of an already diagnosed cancer in an individual. By “stabilization”, it is meant the prevention of evolution of cancer into advanced or metastatic stage in patients with early stage cancer.
- The term “subject” as used herein refers to mammals. For examples, mammals contemplated by the present invention include human, primates, domesticated animals such as cattle, sheep, pigs, horses, laboratory rodents and the like.
- The term “effective amount” as used herein refers to an amount of at least one polypeptide, cells loaded with said polypeptide, composition or pharmaceutical formulation thereof according to the invention, that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought. In one embodiment, the effective amount is a “therapeutically effective amount” for the alleviation of the symptoms of the disease or condition being treated. In another embodiment, the effective amount is a “prophylactically effective amount” for prophylaxis of the symptoms of the disease or condition being prevented. The term also includes herein the amount of active polypeptide sufficient to reduce the progression of the disease, notably to reduce or inhibit the tumor growth or infection and thereby elicit the response being sought (i.e. an “inhibition effective amount”).
- The term “efficacy” of a treatment according to the invention can be measured based on changes in the course of disease in response to a use or a method according to the invention. For example, the efficacy of a treatment of cancer can be measured by a reduction of tumor volume, and/or an increase of progression free survival time, and/or a decreased risk of relapse post-resection for primary cancer. More specifically for cancer treated by immunotherapy, assessment of efficacy can be by the spectrum of clinical patterns of antitumor response for immunotherapeutic agents through novel immune-related response criteria (irRC), which are adapted from Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) criteria (J. Natl. Cancer Inst. 2010, 102(18): 1388-1397). The efficacy of prevention of infectious disease is ultimately assessed by epidemiological studies in human populations, which often correlates with titres of neutralizing antibodies in sera, and induction of multifunctional pathogen specific T cell responses. Preclinical assessment can include resistance to infection after challenge with infectious pathogen. Treatment of an infectious disease can be measured by inhibition of the pathogen's growth or elimination of the pathogen (and, thus, absence of detection of the pathogen), correlating with pathogen specific antibodies and/or T cell immune responses.
- The term “pharmaceutical formulation” refers to preparations which are in such a form as to permit biological activity of the active ingredient(s) to be unequivocally effective and which contain no additional component which would be toxic to subjects to which the said formulation would be administered.
- In a first embodiment, it is provided an isolated polypeptide comprising:
-
- (i) a protein transduction domain consisting of ZEBRA or a fragment thereof that retains the capacity of internalization,
- (ii) at least one, preferably at least two, CD4+ epitope(s); and
- (iii) at least one, preferably at least two, CD8+ epitope(s).
- In the polypeptide according to the invention, “ZEBRA” covers the basic-leucine zipper (bZIP) transcriptional activator of the Epstein-Barr virus (EBV), as well as a truncated form thereof retaining the capacity of internalization, such as the ZEBRA fragment comprising or consisting of amino acid sequence SEQ ID NO: 8, or any peptide with an identical or similar amino acid sequence, provided said ZEBRA fragment or identical or similar peptide retains the capacity of internalization of the protein comprising it.
- Internalization of the fusion protein of the invention comprising ZEBRA or ZEBRA fragment can be checked by standard methods known to one skilled in the art, including flow cytometry or fluorescence microscopy of live and fixed cells, immunocytochemistry of cells transduced with said fusion protein, and Western blot.
- In a preferred aspect, the polypeptide of the invention comprises a ZEBRA fragment comprising or consisting of SEQ ID NO: 8 or any peptide having at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with SEQ ID NO: 8.
- The percentage of identity between two amino acid sequences or two nucleic acid sequences can be determined by visual inspection and/or mathematical calculation, or more easily by comparing sequence information using a computer program such as Clustal package version 1.83.
- Therefore, according to one aspect of the invention, the ZEBRA protein or fragment thereof that is comprised in the polypeptide of the invention comprises an amino acid sequence having at least one conservatively substituted amino acid from the native sequence, meaning that a given amino acid residue is replaced by a residue having similar physiochemical characteristics. Generally, substitutions for one or more amino acids present in the native amino acid sequence should be made conservatively. Examples of conservative substitutions include substitution of one aliphatic residue for another, such as Ile, VaI, Leu, or Ala for one another, or substitutions of one polar residue for another, such as between Lys and Arg; Glu and Asp; or Gln and Asn. Other such conservative substitutions, for example, substitutions of entire regions having similar hydrophobicity properties, are well known (Kyte and Doolittle, 1982, J. Mol. Biol. 157(1): 105-132).
- The CD4+ epitope(s) comprised in the polypeptide of the invention correspond(s) to antigenic determinant(s) of a tumor-associated antigen, a tumor-specific antigen, or an antigenic protein from a pathogen. The CD4+ epitopes comprised in the polypeptide of the invention generally, and preferably, consist of about 12-25 amino acids. They can also consist of about 8-25 amino acids or about 6-100 amino acids.
- The CD8+ epitope(s) comprised in the polypeptide of the invention correspond(s) to antigenic determinant(s) of an antigen such as a tumor-associated antigen, a tumor-specific antigen, or an antigenic protein from a pathogen. The CD8+ epitopes comprised in the polypeptide of the invention generally, and preferably, consist of about 8-11 amino acids. They may also consist of about 8-15 amino acids or about 6-100 amino acids.
- It will be clear for one skilled in the art that each of the epitopes comprised in the polypeptide of the invention can be either directly linked to each other or linked via spacers consisting of a few amino acids present between two successive epitopes.
- In a specific aspect of the invention, two successive epitopes comprised in the polypeptide of the invention are linked to each other by spacers consisting of the natural flanking regions of said epitopes. Preferably, the spacer used to link a first epitope to a second epitope consists of about 8 amino acids corresponding to about 4 amino acids of the flanking region of the first epitope, followed by about 4 amino acids of the flanking region of the second epitope.
- In a particular aspect of the invention, the CD4+ and CD8+ epitopes are antigenic determinants from a tumor-associated antigen or a tumor-specific antigen.
- Exemplary tumor-associated antigens may be selected from the group of Melan A, MART-1, melanoma antigen family (MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A9, MAGE-A10, MAGE-A12, MAGE-C1, MAGE-C2), cancer/testis antigen family (LAGE-1, LAGE2), synovial sarcoma X breakpoint 2 (SSX-2), synovial sarcoma X breakpoint 4 (SSX-4), Transient axonal glycoprotein family (TAG-1, TAG-2, TAG-72), Taxol-resistant-associated gene 3 (TRAG-3), gp100, gp75, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2/glioblastoma oncogene homolog (HER-2/neu), prostate specific antigen (PSA), mucin 1(MUC-1), mucin 16 (CA-125), tumor protein p53, mammaglobin-A, acid phosphatase prostate (PAP), tyrosine-related protein 2 (TRP-2), tyrosinase, kallikrein 4, carcinoembryonic antigen-related cell adhesion molecule 5 (CEA), preferentially expressed antigen in melanoma (PRAME), hydrolase prostate-specific membrane antigen 1 (PSMA), renal tumor antigen (RAGE-1), regulator of G-protein signaling 5 (RGS5), ring finger protein 43 (RNF43), sex determining region Y-box 10 (SOX-10), six transmembrane epithelial antigen of the prostate 1 (STEAP1), Wils tumor 1 (WT1), B melanoma antigen (BAGE-1), G antigen family (GAGE 1, 2, 8, 3, 4, 5, 6, 7), mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase (GnTV), sarcoma antigen 1 (SAGE), sperm autoantigenic protein 17 (SP17), dopachrome tautomerase (TRP2), X antigen family, member 1B (XAGE-1b), KK-LC-1, KM-HN-1, ankyrin repeat domain 30A (NY-BR-1), G protein-coupled receptor 143 (OA1), RAB38 member RAS oncogene family, cyclin D1, vascular endothelial growth factor A (VEGF), fibroblast growth factor 5 (FGF5), Stn, KSA (17-1A), RAS, EGF-R, GD2, GM2, GD3, Anti-Id, CD20, CD19, CD22, CD36, Aberrant class II, B1, CD25, or BPV, EPH receptor A2 (EphA2), IL-13 receptor α2 chain (IL13Rα2), chitinase 3-like 1 (CHI3L1,YKL40), ADP-Ribosylation factor 4-like (ARF4L), UDP-Gal:βGlcNAc β1,3-galactosyltransferase polypeptide 3 (GALT3), squamous cell carcinoma antigen recognized by T cells 1 (SART-1), squamous cell carcinoma antigen recognized by T cells 3 (SART-3), Antigen isolated from immunoselected melanoma-2 (AIM-2), type III variant of the epidermal growth factor receptor EGFRvIII, Brevican (BCA), chitinase 3-like 2 (CHI), chondroitin sulfate proteoglycan 4, fatty acid binding protein 7, insulin-like growth factor 2 mRNA binding protein 3, neuroligin 4, X-linked, neuronal cell adhesion molecule, protein tyrosine phosphatase receptor-type, Z polypeptide 1, tenascin C, surviving, met proto-oncogene.
- However, any epitope of any cancer- or tumor-associated antigen, as well as any epitope of any tumor-specific antigen, may be used.
- Examples of tumor-associated antigens, tumor-specific antigens, and epitopes thereof, which can be comprised in the polypeptides of the invention are disclosed in Tables 1-4. This list is not limitative. Underlined are HLA alleles of MHC class II.
-
TABLE 1 “Tumor-specific antigens resulting from mutations”: antigens that are unique to the tumor of an individual patient or restricted to very few patients HLA Cancer Antigen allele Epitope chronic breakpoint cluster A2 SSKALQRPV myeloid region-c B8 (SEQ ID leukemia (BCR)-abl oncogene 1, DR4 NO: 9) (ABL) fusion protein DR9 GFKQSSKAL (b3a2) (SEQ ID NO: 10) ATGFKQSSKAL QRPVAS (SEQ ID NO: 11) ATGFKQSSKAL QRPVAS (SEQ ID NO: 11) acute ets variant 6 (ETV6) A2 RIAECILGM lympho- runt-related tran- DP5 (SEQ ID blastic scription factor 1 DP17 NO: 12) leukemia (AML1) fusion protein IGRIAECILG MNPSR (SEQ ID NO: 13) IGRIAECILG MNPSR (SEQ ID NO: 13) glioma type III variant of the A2 LEEKKGNYV epidermal growth factor (SEQ ID receptor EGFRvIII NO: 14) -
TABLE 2 “Shared tumor-specific antigens”: Antigens that are shared between many tumors but not present in normal tissues HLA Antigen allele Epitope coiled-coil domain A24 NYNNFYRFL (SEQ ID NO: 15) containing 110 A24 EYSKECLKEF (SEQ ID NO: 16) (KM-HN-1) A24 EYLSLSDKI (SEQ ID NO: 17) cancer/testis antigen 2 A2 MLMAQEALAFL (SEQ ID NO: 18) (LAGE-1) A2 SLLMWITQC (SEQ ID NO: 19) A31 LAAQERRVPR (SEQ ID NO: 20) A68 ELVRRILSR (SEQ ID NO: 21) B7 APRGVRMAV (SEQ ID NO: 22) DP4 SLLMWITQCFLPVF (SEQ ID NO: 23) DR3 QGAMLAAQERRVPRAAEVPR (SEQ ID DR4 NO: 24) DR11 AADHRQLQLSISSCLQQL (SEQ ID NO: DR12 25) DR13 CLSRRPWKRSWSAGSCPGMPHL (SEQ DR15 ID NO: 26) CLSRRPWKRSWSAGSCPGMPHL (SEQ ID NO: 26) ILSRDAAPLPRPG (SEQ ID NO: 27) AGATGGRGPRGAGA (SEG ID NO: 28) melanoma antigen family A1 EADPTGHSY (SEQ ID NO: 29) A, 1 (MAGE-A1) A2 KVLEYVIKV (SEQ ID NO: 30) A3 SLFRAVITK (SEQ ID NO: 31) A68 EVYDGREHSA (SEQ ID NO: 32) B7 RVRFFFPSL (SEQ ID NO: 33) B35 EADPTGHSY (SEQ ID NO: 29) B37 REPVTKAEML (SEQ ID NO: 34) B53 DPARYEFLW (SEQ ID NO: 35) B57 ITKKVADLVGF (SEQ ID NO: 36) Cw2 SAFPTTINF (SEQ ID NO: 37) Cw3 SAYGEPRKL (SEQ ID NO: 38) Cw16 SAYGEPRKL (SEQ ID NO: 38) DP4 TSCILESLFRAVITK (SEQ ID NO: 39) DP4 PRALAETSYVKVLEY (SEQ ID NO: 40) DR13 FLLLKYRAREPVTKAE (SEQ ID NO: 41) DR15 EYVIKVSARVRF (SEQ ID NO: 42) melanoma antigen family A2 YLQLVFGIEV (SEQ ID NO: 43) A, 2 (MAGE-A2) A24 EYLQLVFGI (SEQ ID NO: 44) B37 REPVTKAEML (SEQ ID NO: 34) Cw7 EGDCAPEEK (SEQ ID NO: 45) DR13 LLKYRAREPVTKAE (SEQ ID NO: 46) melanoma antigen family A1 EVDPIGHLY (SEQ ID NO: 47) A, 3 (MAGE-A3) A2 FLWGPRALV (SEQ ID NO: 48) A2 KVAELVHFL (SEQ ID NO: 49) A24 TFPDLESEF (SEQ ID NO: 50) A24 VAELVHFLL (SEQ ID NO: 51) B18 MEVDPIGHLY (SEQ ID NO: 52) B35 EVDPIGHLY (SEQ ID NO: 47) B37 REPVTKAEML (SEQ ID NO: 34) B40 AELVHFLLL (SEQ ID NO: 53) B44 MEVDPIGHLY (SEQ ID NO: 52) B52 WQYFFPVIF (SEQ ID NO: 54) Cw7 EGDCAPEEK (SEQ ID NO: 45) DP4 KKLLTQHFVQENYLEY (SEQ ID NO: 55) DQ6 KKLLTQHFVQENYLEY (SEQ ID NO: 55) DR1 ACYEFLWGPRALVETS (SEQ ID NO: 56) DR4 RKVAELVHFLLLKYR (SEQ ID NO: 57) DR4 VIFSKASSSLQL (SEQ ID NO: 58) DR7 VIFSKASSSLQL (SEQ ID NO: 58) DR7 VFGIELMEVDPIGHL (SEQ ID NO: 59) DR11 GDNQIMPKAGLLIIV (SEQ ID NO: 60) DR11 TSYVKVLHHMVKISG (SEQ ID NO: 61) DR13 RKVAELVHFLLLKYRA (SEQ ID NO: 62) DR13 FLLLKYRAREPVTKAE (SEQ ID NO: 41) melanoma antigen family A1 EVDPASNTY (SEQ ID NO: 63) A, 4 (MAGE-A4) A2 GVYDGREHTV (SEQ ID NO: 64) A24 NYKRCFPVI (SEQ ID NO: 65) B37 SESLKMIF (SEQ ID NO: 66) melanoma antigen family A34 MVKISGGPR (SEQ ID NO: 67) A, 6 (MAGE-A6) B35 EVDPIGHVY (SEQ ID NO: 68) B37 REPVTKAEML (SEQ ID NO: 34) Cw7 EGDCAPEEK (SEQ ID NO: 45) Cw16 ISGGPRISY (SEQ ID NO: 69) DR13 LLKYRAREPVTKAE (SEQ ID NO: 46) melanoma antigen family A2 ALSVMGVYV (SEQ ID NO: 70) A, 9 (MAGE-A9) melanoma antigen family A2 GLYDGMEHL (SEQ ID NO: 71) A, 10 (MAGE-A10) B53 DPARYEFLW (SEQ ID NO: 35) melanoma antigen family A2 FLWGPRALV (SEQ ID NO: 48) A, 12 (MAGE-Al2) Cw7 VRIGHLYIL (SEQ ID NO: 72) Cw7 EGDCAPEEK (SEQ ID NO: 45) DP4 REPFTKAEMLGSVIR (SEQ ID NO: 73) DR13 AELVHFLLLKYRAR (SEQ ID NO: 74) melanoma antigen family DQ6 SSALLSIFQSSPE (SEQ ID NO: 75) C, 1 (MAGE-C1) DQ6 SFSYTLLSL (SEQ ID NO: 76) DR15 VSSFFSYTL (SEQ ID NO: 77) melanoma antigen family A2 LLFGLALIEV (SEQ ID NO: 78) C, 2 (MAGE-C2) A2 ALKDVEERV (SEQ ID NO: 79) B44 SESIKKKVL (SEQ ID NO: 80) cancer/testis antigen 1B A2 SLLMWITQC (SEQ ID NO: 19) (NY-ESO 1/LAGE-2) A2 MLMAQEALAFL (SEQ ID NO: 18) A31 ASGPGGGAPR (SEQ ID NO: 81) A31 LAAQERRVPR (SEQ ID NO: 20) A68 TVSGNILTIR (SEQ ID NO: 82) B7 APRGPHGGAASGL (SEQ ID NO: 83) B35 MPFATPMEA (SEQ ID NO: 84) B49 KEFTVSGNILTI (SEQ ID NO: 85) B51 MPFATPMEA (SEQ ID NO: 84) Cw3 LAMPFATPM (SEQ ID NO: 86) Cw6 ARGPESRLL (SEQ ID NO: 87) DP4 SLLMWITQCFLPVF (SEQ ID NO: 23) DP4 LLEFYLAMPFATPMEAELARRSLAQ DR1 (SEQ ID NO: 88) DR1 LLEFYLAMPFATPMEAELARRSLAQ DR1 (SEQ ID NO: 88) DR2 EFYLAMPFATPM (SEQ ID NO: 89) DR3 PGVLLKEFTVSGNILTIRLTAADHR (SEQ DR4 ID NO: 90) DR4 RLLEFYLAMPFA (SEQ ID NO: 91) DR4 QGAMLAAQERRVPRAAEVPR (SEQ ID DR4 NO: 24) DR4 PFATPMEAELARR (SEQ ID NO: 92) DR52b PGVLLKEFTVSGNILTIRLT (SEQ ID NO: DR7 93) DR7 VLLKEFTVSG (SEQ ID NO: 94) DR8 AADHRQLQLSISSCLQQL (SEQ ID NO: DR9 25) DR15 LLEFYLAMPFATPMEAELARRSLAQ (SEQ ID NO: 88) LKEFTVSGNILTIRL (SEQ ID NO: 95) PGVLLKEFTVSGNILTIRLTAADHR (SEQ ID NO: 90) LLEFYLAMPFATPMEAELARRSLAQ (SEQ ID NO: 88) KEFTVSGNILT (SEQ ID NO: 96) LLEFYLAMPFATPM (SEQ ID NO: 97) AGATGGRGPRGAGA (SEQ ID NO: 28) synovial sarcoma, X A2 KASEKIFYV (SEQ ID NO: 98) breakpoint 2 (SSX-2) DP1 EKIQKAFDDIAKYFSK (SEQ ID NO: 99) DR3 WEKMKASEKIFYVYMKRK (SEQ ID NO: DR4 100) DR11 KIFYVYMKRKYEAMT (SEQ ID NO: 101) KIFYVYMKRKYEAM (SEQ ID NO: 102) synovial sarcoma, X DP10 INKTSGPKRGKHAWTHRLRE (SEQ ID breakpoint 4 (SSX-4) DR3 NO: 103) DR8 YFSKKEWEKMKSSEKIVYVY (SEQ ID DR8 NO: 104) DR11 MKLNYEVMTKLGFKVTLPPF (SEQ ID DR15 NO: 105) DR52 KHAWTHRLRERKQLVVYEEI (SEQ ID NO: 106) LGFKVTLPPFMRSKRAADFH (SEQ ID NO: 107) KSSEKIVYVYMKLNYEVMTK (SEQ ID NO: 108) KHAWTHRLRERKQLVVYEEI (SEQ ID NO: 106) Transient axonal A2 SLGWLFLLL (SEQ ID NO: 109) glycoprotein 1 (TAG-1) B8 LSRLSNRLL (SEQ ID NO: 110) Taxol-resistant-associated DR1 CEFHACWPAFTVLGE (SEQ ID NO: 111) gene 3 (TRAG-3) DR4 CEFHACWPAFTVLGE (SEQ ID NO: 111) DR7 CEFHACWPAFTVLGE (SEQ ID NO: 111) -
TABLE 3 “Differentiation antigens”: Antigens that are shared between many tumors, and are also expressed in the normal tissue of origin of the malignancy HLA Cancer Antigen allele Epitope Gut carcinoembryonic A2 YLSGANLN (SEQ ID NO: 112) carcinoma antigen-related cell A2 IMIGVLVGV (SEQ ID NO: 113) adhesion molecule 5 A2 GVLVGVALI (SEQ ID NO: 114) (CEA) A3 HLFGYSWYK (SEQ ID NO: 115) A24 QYSWFVNGTF (SEQ ID NO: 116) A24 TYACFVSNL (SEQ ID NO: 117) DR3 AYVCGIQNSVSANRS (SEQ ID NO: 118) DR4 DTGFYTLHVIKSDLVNEEATGQFRV DR4 (SEQ ID NO: 119) DR7 YSWRINGIPQQHTQV (SEQ ID NO: 120) DR7 TYYRPGVNLSLSC (SEQ ID NO: 121) DR9 EIIYPNASLLIQN (SEQ ID NO: 122) DR11 YACFVSNLATGRNNS (SEQ ID NO: DR13 123) DR14 LWWVNNQSLPVSP (SEQ ID NO: 124) DR14 LWWVNNQSLPVSP (SEQ ID NO: 124) DR14 LWWVNNQSLPVSP (SEQ ID NO: 124) EIIYPNASLLIQN (SEQ ID NO: 122) NSIVKSITVSASG (SEQ ID NO: 125) Melanoma gp100/Pme17 A2 KTWGQYWQV (SEQ ID NO: 126) A2 (A)MLGTHTMEV (SEQ ID NO: 127) A2 ITDQVPFSV (SEQ ID NO: 128) A2 YLEPGPVTA (SEQ ID NO: 129) A2 LLDGTATLRL (SEQ ID NO: 130) A2 VLYRYGSFSV (SEQ ID NO: 131) A2 SLADTNSLAV (SEQ ID NO: 132) A2 RLMKQDFSV (SEQ ID NO: 133) A2 RLPRIFCSC (SEQ ID NO: 134) A3 LIYRRRLMK (SEQ ID NO: 135) A3 ALLAVGATK (SEQ ID NO: 136) A3 IALNFPGSQK (SEQ ID NO: 137) A3 ALNFPGSQK (SEQ ID NO: 138) A11 ALNFPGSQK (SEQ ID NO: 138) A24 VYFFLPDHL (SEQ ID NO: 139) A32 RTKQLYPEW (SEQ ID NO: 140) A68 HTMEVTVYHR (SEQ ID NO: 141) B7 SSPGCQPPA (SEQ ID NO: 142) B35 VPLDCVLYRY (SEQ ID NO: 143) B35 LPHSSSHWL (SEQ ID NO: 144) Cw8 SNDGPTLI (SEQ ID NO: 145) DQ6 GRAMLGTHTMEVTVY (SEQ ID NO: DR4 146) DR7 WNRQLYPEWTEAQRLD (SEQ ID NO: DR7 147) DR53 TTEWVETTARELPIPEPE (SEQ ID NO: 148) TGRAMLGTHTMEVTVYH (SEQ ID NO: 149) GRAMLGTHTMEVTVY (SEQ ID NO: 146) Prostate Kallikrein 4 DP4 SVSESDTIRSISIAS (SEQ ID NO: 150) cancer DP4 LLANGRMPTVLQCVN (SEQ ID NO: DR7 151) RMPTVLQCVNVSVVS (SEQ ID NO: 152) Breast cancer Mammaglobin-A A3 PLLENVISK (SEQ ID NO: 153) melanoma Melan-A/MART-1 A2 (E)AAGIGILTV (SEQ ID NO: 154) A2 ILTVILGVL (SEQ ID NO: 155) B35 EAAGIGILTV (SEQ ID NO: 156) B45 AEEAAGIGIL(T) (SEQ ID NO: 157) Cw7 RNGYRALMDKS (SEQ ID NO: 158) DQ6 EEAAGIGILTVI (SEQ ID NO: 159) DR1 AAGIGILTVILGVL (SEQ ID NO: 160) DR1 APPAYEKLpSAEQ (phosphopeptide) DR3 (SEQ ID NO: 161) DR4 EEAAGIGILTVI (SEQ ID NO: 159) DR11 RNGYRALMDKSLHVGTQCALTRR DR52 (SEQ ID NO: 162) MPREDAHFIYGYPKKGHGHS (SEQ ID NO: 163) KNCEPVVPNAPPAYEKLSAE (SEQ ID NO: 164) Prostate acid phosphatase, A2 FLFLLFFWL (SEQ ID NO: 165) carcinoma prostate (PAP) A2 TLMSAMTNL (SEQ ID NO: 166) A2 ALDVYNGLL (SEQ ID NO: 167) Prostate prostate specific A2 FLTPKKLQCV (SEQ ID NO: 168) carcinoma antigen (PSA) A2 VISNDVCAQV (SEQ ID NO: 169) Melanoma tyrosinase-related A31 MSLQRQFLR (SEQ ID NO: 170) protein 1 (TRP- DR4 ISPNSVFSQWRVVCDSLEDYD (SEQ ID 1/qp75) DR15 NO: 171) SLPYWNFATG (SEQ ID NO: 172) Melanoma tyrosinase-related A2 SVYDFFVWL (SEQ ID NO: 173) protein 2 (TRP-2) A2 TLDSQVMSL (SEQ ID NO: 174) A31 LLGPGRPYR (SEQ ID NO: 175) A33 LLGPGRPYR (SEQ ID NO: 175) Cw8 ANDPIFVVL (SEQ ID NO: 176) DR3 QCTEVRADTRPWSGP (SEQ ID NO: DR15 177) ALPYWNFATG (SEQ ID NO: 178) Melanoma tyrosinase A1 KCDICTDEY (SEQ ID NO: 179) A1 SSDYVIPIGTY (SEQ ID NO: 180) A2 MLLAVLYCL (SEQ ID NO: 181) A2 CLLWSFQTSA (SEQ ID NO: 182) A2 YMDGTMSQV (SEQ ID NO: 183) A24 AFLPWHRLF (SEQ ID NO: 184) A26 QCSGNFMGF (SEQ ID NO: 185) B35 TPRLPSSADVEF (SEQ ID NO: 186) B35 LPSSADVEF (SEQ ID NO: 187) B38 LHHAFVDSIF (SEQ ID NO: 188) B44 SEIWRDIDF (SEQ ID NO: 189) DR4 QNILLSNAPLGPQFP (SEQ ID NO: 190) DR4 SYLQDSDPDSFQD (SEQ ID NO: 191) DR15 FLLHHAFVDSIFEQWLQRHRP (SEQ ID NO: 192) -
TABLE 4 “Overexpressed antigens”: Antigens that are shared between many tumors, over- expressed in tumors and are also expressed in a wide variety of normal tissues Normal tissue HLA expression Antigen alleles epitopes Ubiquitous (low enhancer of zeste A2 FMVEDETVL (SEQ ID NO: level) homolog 2 (EZH-2) A2 193) A24 FINDEIFVEL (SEQ ID NO: 194) A24 KYDCFLHPF (SEQ ID NO: 195) KYVGIEREM (SEQ ID NO: 196) Ubiquitous (low v-erb-b2 erythroblastic A2 KIFGSLAFL (SEQ ID NO: 197) level) leukemia viral oncogene A2 IISAVVGIL (SEQ ID NO: 198) homolog 2, A2 ALCRWGLLL (SEQ ID NO: neuro/glioblastoma A2 199) derived oncogene A2 ILHNGAYSL (SEQ ID NO: 200) homolog (HER-2/neu) A2 RLLQETELV (SEQ ID NO: 201) A2 VVLGVVFGI (SEQ ID NO: 202) A2 YMIMVKCWMI (SEQ ID NO: A2 203) A2 HLYQGCQVV (SEQ ID NO: A2 204) A2 YLVPQQGFFC (SEQ ID NO: A2 205) A3 PLQPEQLQV (SEQ ID NO: 206) A24 TLEEITGYL (SEQ ID NO: 207) ALIHHNTHL (SEQ ID NO: 208) PLTSIISAV (SEQ ID NO: 209) VLRENTSPK (SEQ ID NO: 210) TYLPTNASL (SEQ ID NO: 211) liver alpha-foetoprotein A2 GVALQTMKQ (SEQ ID NO: A2 212) DR13 FMNKFIYEI (SEQ ID NO: 213) QLAVSVILRV (SEQ ID NO: 214) glandular mucin 1, cell surface A2 STAPPVHNV (SEQ ID NO: 215) epithelia associated (MUC-1) A2 LLLLTVLTV (SEQ ID NO: 216) DR3 PGSTAPPAHGVT (SEQ ID NO: 217) Ubiquitous (low tumor protein p53 (p53) A2 LLGRNSFEV (SEQ ID NO: 218) level) A2 RMPEAAPPV (SEQ ID NO: 219) B46 SQKTYQGSY (SEQ ID NO: DP5 220) DR14 PGTRVRAMAIYKQ (SEQ ID NO: 221) HLIRVEGNLRVE (SEQ ID NO: 222) Testis, ovary, preferentially expressed A2 VLDGLDVLL (SEQ ID NO: endometrium, antigen in melanoma A2 223) adrenals (PRAME) A2 SLYSFPEPEA (SEQ ID NO: A2 224) A24 ALYVDSLFFL (SEQ ID NO: 225) SLLQHLIGL (SEQ ID NO: 226) LYVDSLFFL (SEQ ID NO: 227) Prostate, Central hydrolase (prostate- A24 NYARTEDFF (SEQ ID NO: 228) Nervous System, specific membrane liver antigen) 1 (PSMA) retina renal tumor antigen A2 LKLSGVVRL (SEQ ID NO: 229) (RAGE-1) A2 PLPPARNGGL (SEQ ID NO: B7 230) SPSSNRIRNT (SEQ ID NO: 231) heart, skeletal regulator of G-protein A2 LAALPHSCL (SEQ ID NO: 232) muscle, pericytes signaling 5 (RGS5) A3 GLASFKSFLK (SEQ ID NO: 233) ring finger protein 43 A2 ALWPWLLMA(T) (SEQ ID NO: (RNF43) A24 234) NSQPVWLCL (SEQ ID NO: 235) Ubiquitous (low sex determining region A2 AWISKPPGV (SEQ ID NO: 236) level) Y)-box 10 (SOX-10) A2 SAWISKPPGV (SEQ ID NO: 237) prostate six transmembrane A2 MIAVFLPIV (SEQ ID NO: 238) epithelial antigen of the A2 HQQYFYKIPILVINK (SEQ ID prostate 1 (STEAP1) NO: 239) testis, thymus, Telomerase A2 ILAKFLHWL (SEQ ID NO: 240) bone marrow, A2 RLVDDFLLV (SEQ ID NO: 241) lymph nodes DR7 RPGLLGASVLGLDDI (SEQ ID DR11 NO: 242) LTDLQPYMRQFVAHL (SEQ ID NO: 243) testis, ovary, Wils tumor 1 (WT1) A1 TSEKRPFMCAY (SEQ ID NO: bone marrow, A24 244) spleen DP5 CMTWNQMNL (SEQ ID NO: DR4 245) LSHLQMHSRKH (SEQ ID NO: 246) KRYFKLSHLQMHSRKH (SEQ ID NO: 247) Skin, lung, small EPH receptor A2 A2 TLADFDPRV (SEQ ID NO: 248) intestine (EphA2) Ubiquitous, low sex-determining region A2 ALSPASSSRSV (SEQ ID NO: level Y-box protein 2 (SOX2) 249) Reactive chitinase 3-like 1 A2 SIMTYDFHGA (SEQ ID NO: astrocytes, (CHI3L1,YKL40) 250) macrophages, chondrocytes, neutrophils synovial cells Ubiquitous (at adenosine diphosphate- A2 FLPHFQALHV (SEQ ID NO: mRNA level) ribosylation factor 4-like 251) (ARF4L) protein Ubiquitous, low squamous cell A24 EYRGFTQDF (SEQ ID NO: 252) level carcinoma antigen recognized by T cells 1 (SART-1) Ubiquitous, low squamous cell A24 VYDYNCHVDL (SEQ ID NO: level carcinoma antigen 253) recognized by T cells 3 (SART-3) Lung epithelial IL-13 receptor a2 chain A2 ALPFGFILV (SEQ ID NO: 254) cells, fibroblasts Lung, kidney, UDP-Gal:βG1cNAc A2 TIMAFRWVT (SEQ ID NO: spleen β1,3- 255) galactosyltransferase, polypeptide 3 (GALT3) Note that the epitopes of the 8 last antigens of Table 4 have been described in glioma. - In another aspect of the invention, the CD4+ and CD8+ epitopes are antigenic determinants from a pathogen antigenic protein.
- Examples of viral antigens can be selected from the group consisting of viral meningitis, tuberculosis, encephalitis, dengue or smallpox, or it can be an antigen of a virus selected from the group consisting of smallpox virus, hepatitis type A, hepatitis type B, hepatitis type C, influenza, varicella, adenovirus, herpes simplex type I (HSV-I), herpes simplex type U (HSV-II), rinderpest, rhinovirus, echovirus, rotavirus, respiratory syncytial virus, human papilloma virus (including HPV 16 and HPV 18), papova virus, cytomegalovirus, echinovirus, arbovirus, huntavirus, coxsackie virus, mumps virus, measles virus, rubella virus, polio virus, human immunodeficiency virus (HIV), human immunodeficiency virus type I (HIV-I), human immunodeficiency virus type II (HIV-II), rabies virus, Human T-lymphotropic virus-1 (HTLV-1), Kaposi's sarcoma herpesvirus (KSHV), Merkel cell polyomavirus (MCV), and Epstein Barr virus. In certain embodiments, the HIV vaccine comprises the GPI antigen or a portion or mutant thereof.
- Examples of bacterial antigens can be selected from the group consisting of antigens of Helicobacter pylori, Chlamydia pneumoniae, Chlamydia trachomatis, Ureaplasma urealyticum, Mycoplasma pneumoniae, Staphylococcus spp., Staphylococcus aureus, Streptococcus spp., Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus viridans, Enterococcus faecalis, Neisseria meningitidis, Neisseria gonorrhoeae, Bacillus anthracis, Salmonella spp., Salmonella typhi, Vibrio cholera, Pasteurella pestis, Pseudomonas aeruginosa, Campylobacter spp., Campylobacter jejuni, Clostridium spp., Clostridium difficile, Mycobacterium spp., Mycobacterium tuberculosis, Treponema spp., Borrelia spp., Borrelia burgdorferi, Leptospria spp., Hemophilus ducreyi, Corynebacterium diphtheria, Bordetella pertussis, Bordetella parapertussis, Bordetella bronchiseptica, hemophilus influenza, Escherichia coli, Shigella spp., Erlichia spp., Rickettsia spp. and combinations thereof.
- Examples of protozoal antigens can be selected from the group consisting of antigens of leishmania, kokzidioa, and trypanosoma.
-
TABLE 5 Examples of epitopes from antigenic protein from pathogens which can be comprised in the polypeptide of the invention HLA Pathogen Antigen allele Epitope Lassa Virus GPC A2 GLVGLVTFL (SEQ ID NO: 256) A2 SLYKGVYEL (SEQ ID NO: 257) A2 YLISIFLHL, (SEQ ID NO: 258) DRB1* NSFYYMKGGVNTFLI 0101 (SEQ ID NO: 259) DRB1* SKTHLNFERSLKAFF 0101 (SEQ ID NO: 260) Human E7 A2 TLGIVZPI Papilloma- (SEQ ID NO: 261) virus E7 A2 YMLDLQPETT (HPV 16) (SEQ ID NO: 262) E7 DR17 CCKCDSTLRLC (SEQ ID NO: 263) Mycobac- CFP10 B4501 AEMKTDAA terium (SEQ ID NO: 264) tubercu- CFP10 B1502 NIRQAGVQY losis (SEQ ID NO: 265) MPT63 DR# MKLTTMIKTAVAVVAM HSP 65 DRB1* AAIATFAAP 030I (SEQ ID NO: 266) KTIAYDEEARR (SEQ ID NO: 267) Chlamydia MOMP A2 RLNMFTPYI tracho- (SEQ ID NO: 268) matis Clos- Tetanus DPI* FNNFTVSFWLRVPKVS tridium toxin 0401 ASHLE tetani (SEQ ID NO: 269) Human GP DP1* TEKLWVTVYYGVPVW Immuno- Nef 0401 (SEQ ID NO: 270) deficiency p24 Cw* KRQEILDLWVY Virus 0701 (SEQ ID NO: 271) (HIV) B*57/ TSTLQEQIAW 5801 (SEQ ID NO: 272) # Promiscuous binding to multiple DR alleles - In a further aspect, the polypeptide of the invention comprises at least two CD4+ epitopes and/or at least two CD8+ epitopes.
- In humans, the epitopes that are presented to CD8+ T cells are bound to highly polymorphic MHC class I molecules, specifically the alleles of HLA-A (>400 alleles), HLA-B (>700 alleles), and HLA-C(>200 alleles). The polymorphic MHC class II isotypes responsible for binding peptides recognized by CD4+ T cells are HLA-DR (
DRA 3 alleles, DRB>500 alleles), HLA-DP (DPA>20 alleles, DPB>100 allotypes) and HLA-DQ (DQA>30 alleles, DQB>60 alleles). Although the HLA genes are extremely polymorphic, the same alleles are frequently associated in the same individual, and within an ethnic group, diversity is more restricted. - Therefore, in order to cover a broad range of epitopes presented in a broad context of MHC molecules representative of a given population, and, thus, to render the polypeptides of the invention useful for patients of disparate MHC alleles, it is preferable that the polypeptides of the invention comprise multiple epitopes restricted by multiple MHC class I or class II molecules of said population.
- Preferably, when two or more CD4+ epitopes are comprised in the polypeptide of the invention, said CD4+ epitopes are restricted by at least two MHC class II molecules of the patient population.
- Preferably, when two or more CD8+ epitopes are comprised in the polypeptide of the invention, said CD8+ epitopes are restricted by at least two MHC class I molecules of the patient population.
- More preferably, when two or more CD4+ epitopes and two or more CD8+ epitopes are comprised in the polypeptides of the invention, said CD4+ epitopes are restricted by at least two MHC class II molecules and said CD8+ epitopes are restricted by at least two MHC class I molecules of the patient population.
- There is no upper limit as to how many epitopes can be included in the polypeptide of the invention except for practical feasibility. In a specific aspect, the polypeptide of the invention comprises about 10 epitopes, or any number comprised between 10 to 100 epitopes, preferably 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, 60, 70, 80, 90 or 100 epitopes.
- According to another embodiment, it is provided an isolated polynucleotide encoding a polypeptide comprising:
-
- (i) a protein transduction domain consisting of ZEBRA or a fragment thereof that retains the capacity of internalization,
- (ii) at least one, preferably at least two, CD4+ epitope(s); and
- (iii) at least one, preferably at least two, CD8+ epitope(s).
- In a preferred aspect of the polynucleotide of the invention, the protein transduction domain comprises a nucleotide sequence having at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with SEQ ID NO: 7.
- In an even more preferred aspect of the polynucleotide of the invention, the protein transduction domain comprises or consists of the nucleotide sequence SEQ ID NO: 7.
- In another embodiment, it is provided a recombinant vector comprising a polynucleotide according to the invention.
- Numerous expression systems can be used, including without limitation chromosomes, episomes, and derived viruses. More particularly, the recombinant vectors used can be derived from bacterial plasmids, transposons, yeast episomes, insertion elements, yeast chromosome elements, viruses such as baculovirus, papilloma viruses such as SV40, vaccinia viruses, adenoviruses, fox pox viruses, pseudorabies viruses, retroviruses.
- These recombinant vectors can equally be cosmid or phagemid derivatives. The nucleotide sequence can be inserted in the recombinant expression vector by methods well known to a person skilled in the art such as, for example, those that are described in MOLECULAR CLONING: A LABORATORY MANUAL, Sambrook et al., 4th Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y., 2001.
- The recombinant vector can include nucleotide sequences that control the regulation of the polynucleotide expression as well as nucleotide sequences permitting the expression and the transcription of a polynucleotide of the invention and the translation of a polypeptide of the invention, these sequences being selected according to the host cells that are used.
- Thus, for example, an appropriate secretion signal can be integrated in the recombinant vector so that the polypeptide, encoded by the polynucleotide of the invention, will be directed towards the lumen of the endoplasmic reticulum, towards the periplasmic space, on the membrane or towards the extracellular environment. The choice of an appropriate secretion signal may facilitate subsequent protein purification.
- In a further embodiment, it is provided a host cell comprising a recombinant vector according to the invention.
- The introduction of the recombinant vector in a host cell can be carried out according to methods that are well known to a person skilled in the art, such as those described in BASIC METHODS IN MOLECULAR BIOLOGY, Davis et al., 2nd ed., McGraw-Hill Professional Publishing, 1995, and MOLECULAR CLONING: A LABORATORY MANUAL, supra, such as transfection by calcium phosphate, transfection by DEAE dextran, transfection, microinjection, transfection by cationic lipids, electroporation, transduction or infection.
- The host cell can be, for example, bacterial cells such as E. coli, cells of fungi such as yeast cells and cells of Aspergillus, Streptomyces, insect cells, Chinese Hamster Ovary cells (CHO), C127 mouse cell line, BHK cell line of Syrian hamster cells, Human Embryonic Kidney 293 (HEK 293) cells.
- The host cells can be used, for example, to express a polypeptide of the invention. After purification by standard methods, the polypeptide of the invention can be used in a method described hereinafter.
- It is a further object of the invention to provide a method for preparing a polypeptide according to the invention, comprising cultivating a host cell as mentioned above in a culture medium and separating said polypeptide from the culture medium or separating said polypeptide from the host cell lysate after host cell lysis.
- Antigen-Presenting Cells Loaded with the Polypeptide of the Invention
- In another embodiment, it is provided antigen-presenting cells loaded with the polypeptides of the invention.
- In an aspect of the invention, the antigen presenting cells are selected among dendritic cells, macrophages and B-cells. Dendritic cells, in particular dendritic cells (conventional and plasmacytoid) from the patient to be treated, are preferred.
- Methods to extract antigen-presenting cells, in particular dendritic cells, from the patient are known to the skilled person. They include harvesting monocytes or hematopoietic stem cells from bone marrow, cord blood, or peripheral blood. They also include the use of embryonic stem (ES) cells and induced pluripotent stem cells (iPS). Antigen presenting cells, in particular dendritic cells or their precursors, can be enriched by methods including elutriation and magnetic bead based separation, which may involve enrichment for CD14+ precursor cells.
- Methods to load the polypeptide of the invention into the above-mentioned antigen presenting cells and further prepare such cells before administration to the patient are known to one skilled in the art. Preparation of dendritic cells can include their culture or differentiation using cytokines that may include GM-CSF and IL-4. Dendritic cell lines may also be employed. Loading of the polypeptide of the invention to the dendritic cells can involve co-incubation of the polypeptide of the invention with the cells in culture, making use of the intrinsic properties of the invention (i.e. the protein transduction domain). Further culture of the dendritic cells thus loaded to induce efficient maturation can include addition of cytokines including IL-1β, IL-6, TNFα, PGE2, IFNα, and adjuvants which may include poly-IC.
- It is also an object of the invention to provide a method for preparing antigen presenting cells as mentioned above, comprising transducing antigen presenting cells with a polypeptide of the invention, cultivating said cells in a culture medium and separating said cells from the culture medium.
- The invention provides pharmaceutical compositions, in particular vaccine compositions, and methods for treating a subject, preferably a mammalian subject, and most preferably a human patient who is suffering from a medical disorder, and in particular a disorder that can be treated by immunotherapy such as cancers, infectious diseases, autoimmunity disorders and transplant rejections.
- Pharmaceutical compositions, in particular vaccine compositions, or formulations according to the invention may be administered as a pharmaceutical formulation which can contain a polypeptide according to the invention in any form described herein.
- Pharmaceutical compositions, in particular vaccine compositions, or formulations according to the invention may also be administered as a pharmaceutical formulation which can contain antigen presenting cells loaded with a polypeptide according to the invention in any form described herein.
- The compositions according to the invention, together with a conventionally employed adjuvant, carrier, diluent or excipient may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, or in the form of sterile injectable solutions for parenteral (including subcutaneous and intradermal) use by injection or continuous infusion. Injectable compositions are typically based upon injectable sterile saline or phosphate-buffered saline or other injectable carriers known in the art. Such pharmaceutical compositions and unit dosage forms thereof may comprise ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
- Examples of suitable adjuvants include MPL® (Corixa), aluminum-based minerals including aluminum compounds (generically called Alum), ASO1-4, MF59, CalciumPhosphate, Liposomes, Iscom, polyinosinic:polycytidylic acid (polyIC), including its stabilized form poly-ICLC (Hiltonol), CpG oligodeoxynucleotides, Granulocyte-macrophage colony-stimulating factor (GM-CSF), lipopolysaccharide (LPS), Montanide, PLG, Flagellin, QS21, RC529, IC31, Imiquimod, Resiquimod, ISS, and Fibroblast-stimulating lipopeptide (FSL1).
- Compositions of the invention may be liquid formulations including, but not limited to, aqueous or oily suspensions, solutions, emulsions, syrups, and elixirs. The compositions may also be formulated as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain additives including, but not limited to, suspending agents, emulsifying agents, non-aqueous vehicles and preservatives. Suspending agents include, but are not limited to, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminum stearate gel, and hydrogenated edible fats. Emulsifying agents include, but are not limited to, lecithin, sorbitan monooleate, and acacia. Preservatives include, but are not limited to, methyl or propyl p-hydroxybenzoate and sorbic acid. Dispersing or wetting agents include but are not limited to poly(ethylene glycol), glycerol, bovine serum albumin, Tween®, Span®.
- Compositions of the invention may also be formulated as a depot preparation, which may be administered by implantation or by intramuscular injection.
- Solid compositions of this invention may be in the form of tablets or lozenges formulated in a conventional manner. For example, tablets and capsules for oral administration may contain conventional excipients including, but not limited to, binding agents, fillers, lubricants, disintegrants and wetting agents. Binding agents include, but are not limited to, syrup, accacia, gelatin, sorbitol, tragacanth, mucilage of starch and polyvinylpyrrolidone. Fillers include, but are not limited to, lactose, sugar, microcrystalline cellulose, maizestarch, calcium phosphate, and sorbitol. Lubricants include, but are not limited to, magnesium stearate, stearic acid, talc, polyethylene glycol, and silica. Disintegrants include, but are not limited to, potato starch and sodium starch glycollate. Wetting agents include, but are not limited to, sodium lauryl sulfate. Tablets may be coated according to methods well known in the art.
- The compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems.
- According to a particular embodiment, compositions according to the invention are for subcutaneous use.
- In another particular aspect, the compositions according to the invention are adapted for delivery by repeated administration.
- Further materials as well as formulation processing techniques and the like are set out in Part 5 of Remington's Pharmaceutical Sciences, 21st Edition, 2005, Lippincott Williams & Wilkins, which is incorporated herein by reference.
- Another object of the invention is to provide a method of preparing a pharmaceutical composition according to the invention comprising the step of mixing a polypeptide according to the invention or antigen-presenting cells loaded with a polypeptide of the invention, and a pharmaceutically acceptable carrier.
- The polypeptides according to the invention, antigen-presenting cells loaded with the polypeptides of the invention, compositions according to the invention, formulations thereof or a method according to the invention are useful in the prevention and/or treatment of a disease or a disorder, in particular those that can be treated or prevented by immunotherapy such as cancers and infectious diseases.
- Another object of the invention is a vaccination kit for treating, preventing or stabilizing a cancer or an infectious disease, comprising the pharmaceutical composition according to the invention and instructions for use of said pharmaceutical composition.
- According to one embodiment, it is provided a method for eliciting or improving, in a subject, an immunologic response against multiple epitopes that is dependent on CD4+ helper T cells and CD8+ cytotoxic T cells, wherein said method comprises administering a polypeptide of the invention to said subject.
- According to another embodiment, it is provided a method for eliciting or improving, in a subject, an immunologic response against multiple epitopes that is dependent on CD4+ helper T cells and CD8+ cytotoxic T cells, wherein said method comprises administering antigen-presenting cells loaded with a polypeptide of the invention to said subject.
- An immunologic response that is dependent on CD4+ and CD8+ response can be determined by evaluating an inflammatory response, a pro-inflammatory cytokine response, including an increase in the expression of one or more of IFN-γ, TNF-α and IL-2 mRNA or protein relative to the level before administration of the compounds of the invention. It can also be measured by an increase in the frequency or absolute number of antigen-specific T cells after administration of the compounds of the invention, measured by HLA-peptide multimer staining, ELISPOT assays, and delayed type hypersensitivity tests. It can also be indirectly measured by an increase in antigen-specific serum antibodies that are dependent on antigen-specific T helper cells.
- According to another embodiment, it is provided a method for eliciting or improving, in a subject, an immunologic response against multiple epitopes that is restricted by multiple MHC class I molecules and multiple MHC class II molecules, wherein said method comprises administering a polypeptide of the invention.
- According to another aspect, it is provided a method for eliciting or improving, in a subject, an immunologic response against multiple epitopes that is restricted by multiple MHC class I molecules and multiple MHC class II molecules, wherein said method comprises administering antigen presenting cells of the invention to said subject.
- A method for eliciting or improving, in a subject, an immunologic response against multiple epitopes that is restricted by multiple MHC class I molecules and multiple MHC class II molecules can be determined by evaluating a cytokine response, including an increase in the expression of one or more of IFN-γ, TNF-α and IL-2 mRNA or protein relative to the level before administration of the compounds of the invention, after in vitro stimulation of T cells with individual peptides binding to discrete MHC class I and class II molecules on antigen presenting cells. Restriction to different MHC molecules can also be validated by using antigen presenting cells expressing different MHC molecules, or by using MHC blocking antibodies. It can also be measured by an increase in the frequency or absolute number of antigen-specific T cells after administration of the compounds of the invention, measured by HLA-peptide multimer staining, which uses multimers assembled with discrete MHC molecules.
- In a preferred aspect of the methods for eliciting or improving an immunologic response against multiple epitopes according to the invention, the immune response is directed against multiple epitopes of a tumor-associated antigen or a tumor-specific antigen. In another preferred aspect, the immune response is directed against multiple epitopes of an antigenic protein from a pathogen.
- Another embodiment of the invention provides the use of a polypeptide of the invention or the use of antigen-presenting cells loaded with a polypeptide of the invention for the preparation of a medicament for the prevention, treatment or stabilization of a disease or disorder, such as those which can be treated by immunotherapy, including cancers, infectious diseases, autoimmunity disorders and transplant rejections.
- According to another aspect, the invention provides a method of preventing, treating or repressing a disease or disorder such as those which can be treated by immunotherapy, including cancers, infectious diseases, autoimmunity disorders and transplant rejections, wherein said method comprises administering a polypeptide of the invention, antigen presenting cells of the invention, or a pharmaceutical formulation thereof, to said subject.
- In a preferred, uses and methods of the invention comprises administration of a polypeptide according to the invention.
- Preferred cancers for the uses and methods of the invention include brain cancer, prostate cancer, breast cancer, ovarian cancer, esophageal cancer, lung cancer, liver cancer, kidney cancer, melanoma, gut carcinoma, lung carcinoma, head and neck squamous cell carcinoma, chronic myeloid leukemia, colorectal carcinoma, gastric carcinoma, endometrial carcinoma, myeloid leukemia, lung squamous cell carcinoma, acute lymphoblastic leukemia, acute myelogenous leukemia, bladder tumor, promyelocytic leukemia, non-small cell lung carcinoma, sarcoma.
- The cancer may be a solid tumor, blood cancer, or lymphatic cancer. The cancer may be benign or metastatic.
- More preferred cancers are brain tumors, in particular gliomas including glioblastoma multiforme (GBM).
- Preferred infectious diseases for the uses and methods of the invention include diseases caused by viruses, bacteria, fungi, protozoa and multicellular parasites. They include, for instance, Amoebiasis, Anthrax, Buruli Ulcer (Mycobacterium ulcerans), Caliciviruses associated diarrhoea, Campylobacter diarrhoea, Cervical Cancer (Human papillomavirus), Chlamydia trachomatis associated genital diseases, Cholera, Crimean-Congo haemorrhagic fever, Dengue Fever, Diphtheria, Ebola haemorrhagic fever, Enterotoxigenic Escherichia coli (ETEC) diarrhoea, Gastric Cancer (Helicobacter pylori), Gonorrhea, Group A Streptococcus associated diseases, Group B Streptococcus associated diseases, Haemophilus influenzae B pneumonia and invasive disease, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis E diarrhoea, Herpes simplex type 2 genital ulcers, HIV/AIDS, Hookworm Disease, Influenza, Japanese encephalitis, Lassa Fever, Leishmaniasis, Leptospirosi, Liver cancer (Hepatitis B), Liver Cancer (Hepatitis C), Lyme Disease, Malaria, Marburg haemorrhagic fever, Measles, Mumps, Nasopharyngeal cancer (Epstein-Barr virus), Neisseria meningitidis Meningitis, Parainfluenza associated pneumonia, Pertussis, Plague, Poliomyelitis, Rabies, Respiratory syncytial virus (RSV) pneumonia, Rift Valley fever, Rotavirus diarrhoea, Rubella, Schistosomiasis, Severe Acute Respiratory Syndrome (SARS), Shigellosis, Smallpox, Staphylococcus aureus associated diseases, Stomach Cancer (Helicobacter pylori), Streptococcus pneumoniae and invasive disease, Tetanus, Tick-borne encephalitis, Trachoma, Tuberculosis, Tularaemia, Typhoid fever, West-Nile virus associated disease, Yellow fever.
- In a preferred aspect of the use and method of the invention, the antigen presenting cells are dendritic cells, more preferably dendritic cells from the subject to be treated.
- Typically, for cancer treatment, the therapeutically effective dose of a polypeptide according to the invention is from about 0.1 mg to 2 mg per injection.
- Typically, for cancer treatment, the therapeutically effective dose of an antigen presenting cell loaded with a polypeptide according to the invention is from about 0.2 million cells to 2 million cells per injection.
- The dosage administered, as single or multiple doses, to an individual will vary depending upon a variety of factors, including pharmacokinetic properties, patient conditions and characteristics (sex, age, body weight, health, size), extent of symptoms, concurrent treatments, frequency of treatment and the effect desired.
- Compounds, compositions, in particular vaccine compositions, and formulations thereof according to this invention may be administered in any manner including orally, parenterally, intravenously, rectally, or combinations thereof. Parenteral administration includes, but is not limited to, intravenous, intra-arterial, intra-peritoneal, subcutaneous, intradermal and intramuscular. The compositions of this invention may also be administered in the form of an implant, which allows slow release of the compositions as well as a slow controlled i.v. infusion.
- Preferentially, the compounds, compositions, in particular vaccine compositions, and formulations thereof according to the invention are administered subcutaneously.
- In one embodiment of the invention, the administration of the polypeptides, antigen presenting cells and compositions of the invention requires multiple successive injections. Thus, the administration can be repeated at least two times, once as primary immunization injections and, later, as booster injections.
- In a preferred embodiment of the invention, the vaccine composition may be administered repeatedly or continuously. The vaccine composition can be administered repeatedly or continuously for a period of at least 1, 2, 3, or 4 weeks; 2, 3, 4, 5, 6, 8, 10, or 12 months; or 2, 3, 4, or 5 years.
- According to a further embodiment, the administration of the pharmaceutical compositions in the methods and uses according to the invention can be carried out alone or in combination with a co-agent useful for treating and/or stabilizing the disease or disorder to be treated or repressed. In the case of treatment, prevention, or stabilization of a cancer, the administration of the pharmaceutical compositions in the methods and uses according to the invention can be carried out in combination with substances used in conventional chemotherapy directed against solid tumors and for control of establishment of metastases or any other molecule that act by triggering programmed cell death e.g. for example a co-agent selected from Tumor Necrosis Family Members including, but not limited, to Fas Ligand and tumor necrosis factor (TNF)-related apoptosis inducing (TRAIL) ligand. According to a further embodiment, the administration of the pharmaceutical compositions in the methods and uses according to the invention can be carried out in parallel of radiotherapy.
- The invention encompasses the administration of a polypeptide of the invention, or an antigen-presenting cell of the invention, or a pharmaceutical composition thereof according to the invention, wherein it is administered to a subject prior to, simultaneously or sequentially with other therapeutic regimens or co-agents useful for treating, and/or stabilizing a cancer and/or preventing cancer relapsing (e.g. multiple drug regimens), in a therapeutically effective amount. A polypeptide of the invention, or an antigen-presenting cell of the invention, or a pharmaceutical composition thereof according to the invention that is administered simultaneously with said co-agents can be administered in the same or different composition(s) and by the same or different route(s) of administration.
- Said other therapeutic regimens or co-agents may be selected from the group consisting of radiation therapy, chemotherapy, surgery, targeted therapy (including small molecules, peptides and monoclonal antibodies), and anti-angiogenic therapy. Anti-angiogenic therapy is defined herein as the administration of an agent that directly or indirectly targets tumor-associated vasculature.
- According to one embodiment, is provided a pharmaceutical formulation comprising a polypeptide of the invention or an antigen-presenting cell of the invention, combined with at least one co-agent useful for treating and/or stabilizing a cancer and/or preventing a cancer relapsing, and at least one pharmaceutically acceptable carrier.
- According to another embodiment of the invention, the compounds according to the invention and pharmaceutical formulations thereof can be administered after surgery where solid tumors have been removed as a prophylaxis against relapsing and/or metastases.
- In an embodiment, patients according to the invention are patients suffering from a cancer.
- In a particular embodiment, patients according to the invention have been subjected to a chirurgical removal of a tumor.
- In another embodiment, patients according to the invention are patients suffering from an infectious disease.
- References cited herein are hereby incorporated by reference in their entirety. The present invention is not to be limited in scope by the specific embodiments and drawings described herein, which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. The examples illustrating the invention are not intended to limit the scope of the invention in any way.
- The following examples have been conducted to support the effectiveness of the ZEBRA-multiepitopic fusion proteins of the invention in the induction of a cytotoxic T cells and helper T cells dependent immune response.
- Three different constructs (
FIG. 1 ) were engineered and cloned in a modified pET-15b vector deleted for thrombin and stop codons. N-terminal fusion proteins comprising amino acids residues 178-220 of ZEBRA (NCBI Accession Number YP—401673) were made carrying His-Tag allowing protein purification. The amino acid sequence of the ZEBRA fragment comprised in the ZEBRA fusion proteins described in the examples is SEQ ID NO: 8. - Construct 1: ZEBRA-β-lactamase: encodes β-lactamase from E. Coli deleted for the secretion signal (residues 1-23) and residue 24 His was changed to Asp to create an optimal Kozak sequence.
- Construct 2: ZEBRA-OVA: encodes a truncated form of the chicken ovalbumin (OVA234-386). This construction contains both CD8 epitope OVA257-264 and CD4 epitope OVA323-339.
- Construct 3: ZEBRA-MultiE: encodes a chimeric protein with three CD8 epitopes from the ovalbumin OVA257-2645 from lymphocytic choriomengitis virus glycoprotein LCMV-GP33-41 and from the murine tumor-associated antigen GP10025-33 and two CD4 epitopes: OVA323-339 and LCMV-GP61-80. The spacers between each epitope are the natural flanking 4 amino acids residues.
- A standard and reproducible protein delivery protocol for DCs was established using the quantifiable reporter protein β-lactamase and CCF2-AM its membrane-permeable substrate that allows monitoring of free cytoplasmic protein. Indeed, CCF2-AM is a lipophilic and esterified substrate, which can enter into the cells. Endogenous cytoplasmic esterase rapidly converts CCF2-AM into a negatively charged form (CCF2), which is not able to cross cell membranes, including endosomal membranes. Therefore, the β-lactamase transduced into cells with ZEBRA (construct 1) can cleave the CCF2 that is free in the cytoplasm.
- A direct correlation between the protein concentration and time of incubation was observed. With increasing time and protein concentration, higher transduction efficiencies up to 70% were observed. For all the experiments described below a protein concentration of 0.3 μM and a loading time of 4 h were used, reaching transduction efficiencies of 70%. Under these experimental conditions, addition of β-lactamase without ZEBRA did not result in any detectable cleavage of CCF2. This indicated that the protein uptake was in majority mediated by ZEBRA rather than by the phagocytic capacity of dendritic cells.
- Functional MHC I restricted presentation by DCs after loading with a truncated ovalbumin (OVA) protein (amino acids 234-386) fused to the PTDs (construct 2) was verified. Presentation of the immunodominant CD8+ epitope from ovalbumin (SIINFEKL, OVA257-264) was detected with the specific T cells from OT-1 T cell receptor (TCR) transgenic mice in vitro. TCR transgenic mice have all the CD8+ or CD4+ T cells specific for one epitope. The CD8+ TCR transgenic mice used here are OT-1, specific for the OVA257-264 epitope.
- Bone marrow derived dendritic cells (BMDCs) were loaded with ZEBRA-OVA257-264 during 4 h, washed and matured overnight with maturation cocktail containing IFNα, IFNγ, IL-4 and PolyIC (Fujita et al., 2009, Cancer Res. 69:1587-1595). OT-1 cells were stained with the non-toxic dye carboxyfluorescein succinimidyl ester (CFSE). Cell proliferation results in dilution of CFSE, which can be monitored by flow cytometry. CFSE stained OT-1 cells were incubated with matured BMDCs at a ratio 10:1 during 5 day. As positive control, mature BMDCs were pulsed with 10 μM Ova peptide. As negative control, OT-1 T cells were incubated without any stimulation. DCs loaded with ZEBRA-OVA257-264 had the same priming capacity as peptide pulsed DCs with 81% and 93% proliferating CD8+ T cells, respectively. The same experiment was performed with BMDCs loaded with ZEBRA-OVA257-264 after maturation. BMDCs loaded before or after maturation had the same priming capacity with 69% and 70% proliferating CD8+ respectively, confirming that cross-presentation results from ZEBRA-mediated antigen delivery.
- The presentation of the OVA-specific CD4 epitope (OVA323-339) was monitored with the OT-2 TCR transgenic mice. DCs loaded with ZEBRA-OVA257-264 were able to activate OVA-specific CD4+ T-cells.
- Similarly, a chimeric protein (called ZEBRA-MultiE fusion protein corresponding to construct 3) encoding OVA, the tumor-associated antigen gp100 and the viral LCMV-GP peptides was loaded into DCs and MHC I restricted presentation was monitored in vitro with lymphocytes from OT-1 mice, Pmel-1 mice transgenic for the gp100-specific TCR (GP10025-33) and P14 mice transgenic for the LCMV-GP-specific TCR (LCMV-GP33-41), respectively. MHC II restricted presentation was also monitored with lymphocytes from OT-2 mice and SMARTA mice transgenic for the LCMV-GP-specific TCR (LCMV-GP61-80). Multi-epitopic presentation was observed with 3 CD8+ epitopes (
FIGS. 2 ) and 2 CD4+ (FIG. 3 ) epitopes being efficiently presented. The presentation of gp100 was low, but significant. This may reflect the low affinity interaction of murine gp100 with the murine MHC class I molecule H-2Db. The percentage of proliferating T cells after priming with DC loaded with ZEBRA-MultiE is similar to peptide pulsed DCs. - The proliferation of T cells described in the previous results indicates T cell activation through engagement of the T cell receptor (TCR) with the epitope-MHC complex. However, full differentiation to functional T cells includes expression of cytokines including IFNγ, TNFα and some IL-2. Moreover CD4 Th cells can polarize into Th1 (IFNγ+ IL-2+ TNFα+) promoting cell-mediated immune responses, or Th2 (IL-4+) promoting antibody mediated immune response. The goal here was to assess the cytokine profiles of CD8+ and CD4+ T cells activated in vitro. The supernatant was analyzed after 5 days of culture (
FIG. 4 ). CD8+ T cells primed with BMDCs loaded with ZEBRA-MultiE were producing IFNγ and TNFα as the same level as the CD8+ T cells primed with peptide pulsed DCs (FIG. 4 ). No IL-2 was found in the culture supernatant of CD8+ T cells cultivated with ZEBRA-MultiE loaded BMDCs. CD4+ T cells showed a Th1 polarization with secretion of IFNγ and TNFα, and again no IL-2 was found. - To clarify whether the absence of IL-2 in the supernatants reflected consumption by the CD8+ and CD4+ T cells primed with ZEBRA-MultiE loaded BMDCs, intracellular cytokine staining after 4 days of culture was performed. 45% of OT-1 CD8+ T cells were positive for IL-2 expression, and 21% of the P14 CD8+ T cells. Similarly, around 60% of the SMARTA and OT-2 CD4+ T cells were positive for IL-2 expression. It is most likely, that the produced IL-2 is not accumulating in the culture medium but rapidly used by the proliferating T cells. Therefore, in vitro primed T cells by ZEBRA-MultiE loaded BMDCs are able to proliferate as well as producing effector cytokines, including Th1 cytokines that will support cell mediated immunity.
- The potential of ZEBRA to deliver antigens in vivo was then evaluated by either vaccinating with ZEBRA-MultiE transduced DC, or directly with the ZEBRA-MultiE fusion protein.
- For DC vaccination, mice were vaccinated twice with a 14-days interval with type 1 polarized (Fujita et al., 2009, Cancer Res. 69:1587-1595) BMDC (106 mature DCs per vaccination) loaded with ZEBRA-MultiE. Seven days after the second vaccination, cells were isolated from lymph node and spleen, restimulated with the peptides contained in MultiE, and intracellular cytokine expression was measured in both CD4 and CD8 T cell populations (
FIG. 5 ). The proportion of CD8+ (top panel) or CD4+ (bottom panel) T cells expressing each cytokine after in vitro restimulation with each peptide epitope is plotted in the bar chart. The multifunctionality of the response (capacity to express 1, 2, or 3 cytokines) is illustrated in the pie chart. Some multifunctionality (≧2 cytokines) is present for every epitope tested, although the proportions of multifunctional T cells vary according to the epitope. - Mice were vaccinated subcutaneously twice with a 14-days interval with 6 μg ZEBRA-MultiE and 100 μg PolyIC. Seven days after the second vaccination, cells were isolated from lymph node and spleen, restimulated with the peptides contained in ZEBRA-MultiE, and intracellular cytokine expression was measured in both CD4 and CD8 T cell populations (
FIG. 6 ). The proportion of CD8+ (top panel) or CD4+ (bottom panel) T cells expressing each cytokine after in vitro restimulation with each peptide epitope is plotted in the bar chart. The multifunctionality of the response (capacity to express 1, 2, or 3 cytokines) is illustrated in the pie chart. Interestingly, the proportion of cells showing multifunctionality was higher than with the DC based vaccine, including the number of IL-2 expressing cells. Moreover, since the tested epitopes contained in ZEBRA-MultiE are presented by 3 different H-2 molecules, positive T cell responses to these epitopes validates that a T cell immune response restricted by multiple MHC molecules has been induced. The MHC restriction elements for each epitope are: OVA257-264: H-2Kb; OVA323-339: H-2-I-Ab; LCMV-GP33-41:H-2Db; gp10025-33:H-2Db; LCMV-GP61-80:H-2-IAb). - Bone marrow derived dendritic cells from mice on BALB/c background were loaded for 4 h with 0.3 μM Zebra-MultiE and matured overnight with poly ICLC (Hiltonol®). Zebra-MultiE loaded and matured dendritic cells were co-incubated with CFSE stained splenocytes from DO11.10 TCR transgenic mice in which all of the CD4+ T cells are specific for the immunodominant ovalbumin epitope OVA257-264. As negative control, splenocytes were incubated with non-loaded dendritic cells. For the positive control, the dendritic cells were pulsed with peptide. After five days of culture, T cell proliferation by CFSE dilution was monitored by flow cytometry.
- Results of
FIG. 7 show that Zebra-MultiE can be processed and presented by dendritic cells with different MHC molecules. - C57BL/6 mice were vaccinated with PBS for the negative control, 200 μg peptides and 100 μg anti-CD40 subcutaneously and 50 μg Poly ICLC (Hiltonol®) intramuscularly for the positive control or 10 μg ZEBRA-MultiE protein and 100 μg anti-CD40 subcutaneously and 50 μg Poly ICLC (Hiltonol®) intramuscularly. The same day, 1.5×106 CFSE stained splenocytes from either P14 or OT1 TCR transgenic mice were adoptively transferred by intravenous injection. Four days after vaccination/adoptive transfer, the mice were sacrificed and proliferation of adoptively transferred T cell from draining lymph nodes was assessed by CFSE dilution.
- Results of
FIG. 8 show that Zebra-MultiE translocates into endogenous dendritic cells in vivo and is processed, leading to cross-presentation on MHC class I molecules. - C57BL/6 mice were vaccinated twice at 14-days of interval by subcutaneous injection of 10 μg ZEBRA-MultiE protein and 100 μg anti-CD40 and intramuscular injection of 50 μg Poly ICLC (Hiltonol®). Seven days after the boost, the mice were sacrificed and the percentages of CD8+ T cells specific for either OVA323-339, LCMV-GP33-41, or GP10025-33 were assessed in the draining lymph nodes by tetramer staining.
- The results of
FIG. 9 show that vaccination of mouse with ZEBRA-MultiE can induce polyclonal immune responses.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/883,668 US20160031946A1 (en) | 2011-03-11 | 2015-10-15 | Multi-epitopic vaccine |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161451615P | 2011-03-11 | 2011-03-11 | |
US13/415,877 US9187534B2 (en) | 2011-03-11 | 2012-03-09 | Multi-epitopic vaccine |
US14/883,668 US20160031946A1 (en) | 2011-03-11 | 2015-10-15 | Multi-epitopic vaccine |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/415,877 Continuation US9187534B2 (en) | 2011-03-11 | 2012-03-09 | Multi-epitopic vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160031946A1 true US20160031946A1 (en) | 2016-02-04 |
Family
ID=46795780
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/415,877 Active 2032-05-19 US9187534B2 (en) | 2011-03-11 | 2012-03-09 | Multi-epitopic vaccine |
US14/883,668 Abandoned US20160031946A1 (en) | 2011-03-11 | 2015-10-15 | Multi-epitopic vaccine |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/415,877 Active 2032-05-19 US9187534B2 (en) | 2011-03-11 | 2012-03-09 | Multi-epitopic vaccine |
Country Status (1)
Country | Link |
---|---|
US (2) | US9187534B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019070991A1 (en) * | 2017-10-05 | 2019-04-11 | Duke University | Enhancing the efficacy of cancer vaccines |
WO2019173462A1 (en) * | 2018-03-06 | 2019-09-12 | Pepvax, Inc. | Nucleic acid molecules and methods of using the same |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8129184B2 (en) | 2006-09-26 | 2012-03-06 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
CA2700436C (en) * | 2006-09-28 | 2017-04-18 | John S. Yu | Cancer vaccines and vaccination methods |
DK2328923T3 (en) | 2008-09-02 | 2016-03-21 | Cedars Sinai Medical Center | CD133 epitopes |
US9187534B2 (en) * | 2011-03-11 | 2015-11-17 | Universite De Geneve | Multi-epitopic vaccine |
WO2013126402A1 (en) * | 2012-02-20 | 2013-08-29 | University Of Virginia Patent Foundation | Composition and methods for treating melanoma |
KR101861416B1 (en) | 2012-09-13 | 2018-05-25 | 유니베르시떼 드 제네브 | Cell penetrating peptides |
WO2014127296A1 (en) * | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd | Cancer vaccines and vaccination methods |
JP6659535B2 (en) * | 2013-06-28 | 2020-03-04 | オークランド ユニサービシーズ リミティド | Amino acid and peptide conjugates and conjugation methods |
JP2018505152A (en) | 2014-12-23 | 2018-02-22 | アン ブリンブル マーガレット | Amino acid conjugates and peptide conjugates and uses thereof |
US20180133327A1 (en) * | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
KR20180128915A (en) | 2016-02-26 | 2018-12-04 | 오클랜드 유니서비시즈 리미티드 | Amino acid and peptide conjugates and methods of conjugation |
JP7346291B2 (en) * | 2016-09-21 | 2023-09-19 | アマル セラピューティクス エスエー | Fusions containing cell-penetrating peptides, multi-epitopes, and TLR peptide agonists for treating cancer |
CN107056892A (en) * | 2017-05-24 | 2017-08-18 | 上海市普陀区中心医院 | A kind of related specific polypeptide of EBV detections and its related application |
CN108359013A (en) * | 2018-02-07 | 2018-08-03 | 上海交通大学 | A kind of artificial antigen submission nanometer formulation and its application for inside and outside specific amplification T cell |
WO2019196088A1 (en) * | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific t cell receptors |
GB201907413D0 (en) * | 2019-05-24 | 2019-07-10 | Univ Helsinki | Viral vector |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150239938A1 (en) * | 2012-09-13 | 2015-08-27 | Les Hopitaux Universitaires De Geneve | Cell Penetrating Peptides |
US9175048B2 (en) * | 2010-04-26 | 2015-11-03 | Universite Joseph Fourier | Use of peptides as transporters intended for the internalization of molecules of interest into target cells |
US9187534B2 (en) * | 2011-03-11 | 2015-11-17 | Universite De Geneve | Multi-epitopic vaccine |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6750008B1 (en) * | 1999-07-09 | 2004-06-15 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission |
US20060222656A1 (en) * | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
WO2011036211A1 (en) * | 2009-09-23 | 2011-03-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Polypeptides and nucleic acids for treating erbb2-dependent cancers |
WO2011101332A1 (en) * | 2010-02-16 | 2011-08-25 | Proyecto De Biomedicina Cima, S.L. | Compositions based on the fibronectin extracellular domain a for the treatment of melanoma |
ES2930809T3 (en) * | 2010-08-24 | 2022-12-22 | Univ Pittsburgh Commonwealth Sys Higher Education | Interleukin-13 alpha 2 receptor peptide-based brain cancer vaccines |
-
2012
- 2012-03-09 US US13/415,877 patent/US9187534B2/en active Active
-
2015
- 2015-10-15 US US14/883,668 patent/US20160031946A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9175048B2 (en) * | 2010-04-26 | 2015-11-03 | Universite Joseph Fourier | Use of peptides as transporters intended for the internalization of molecules of interest into target cells |
US9187534B2 (en) * | 2011-03-11 | 2015-11-17 | Universite De Geneve | Multi-epitopic vaccine |
US20150239938A1 (en) * | 2012-09-13 | 2015-08-27 | Les Hopitaux Universitaires De Geneve | Cell Penetrating Peptides |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019070991A1 (en) * | 2017-10-05 | 2019-04-11 | Duke University | Enhancing the efficacy of cancer vaccines |
WO2019173462A1 (en) * | 2018-03-06 | 2019-09-12 | Pepvax, Inc. | Nucleic acid molecules and methods of using the same |
CN112292142A (en) * | 2018-03-06 | 2021-01-29 | Pepvax公司 | Nucleic acid molecules and methods of use thereof |
US11844824B2 (en) | 2018-03-06 | 2023-12-19 | Pepvax, Inc. | Nucleic acid molecules and methods of using the same |
Also Published As
Publication number | Publication date |
---|---|
US20120231030A1 (en) | 2012-09-13 |
US9187534B2 (en) | 2015-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9187534B2 (en) | Multi-epitopic vaccine | |
US20220072113A1 (en) | Antigen specific multi epitope vaccines | |
EP2895499B1 (en) | Cell penetrating peptides | |
JP7346291B2 (en) | Fusions containing cell-penetrating peptides, multi-epitopes, and TLR peptide agonists for treating cancer | |
US8263560B2 (en) | HPV 16 peptide vaccine for head and neck cancer | |
CA2511775A1 (en) | Hla-a1,-a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions | |
CA2386341A1 (en) | Heteroclitic analogs and related methods | |
WO2002064057A2 (en) | Use of cell penetrating peptides to generate antitumor immunity | |
Shiku et al. | Development of a cancer vaccine: peptides, proteins, and DNA | |
Miconnet et al. | Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction | |
JP2011506497A5 (en) | ||
US20050063952A1 (en) | Immunogenic CEA | |
US20040002455A1 (en) | Targeted immunogens | |
Marincek et al. | Heat shock protein–antigen fusions lose their enhanced immunostimulatory capacity after endotoxin depletion | |
ZA200605304B (en) | Targeted immunogens | |
Berzofsky et al. | Peptide vaccines against cancer | |
Yin et al. | HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity | |
WO2012026820A2 (en) | Immunotherapeutic method for treating prostate cancer | |
Hariharan et al. | Development and application of PROVAX™ adjuvant formulation for subunit cancer vaccines | |
Ressing et al. | Vaccination Strategies to Induce T-Cell Immunity Against Tumours | |
AU2003216119A1 (en) | Targeted immunogens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HOPITAUX UNIVERSITAIRES DE GENEVE, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DIETRICH, PIERRE-YVES;REEL/FRAME:036801/0102 Effective date: 20110305 Owner name: UNIVERSITE DE GENEVE, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DIETRICH, PIERRE-YVES;REEL/FRAME:036801/0102 Effective date: 20110305 Owner name: UNIVERSITE DE GENEVE, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEROUAZI, MADIHA SABIHA;WALKER, PAUL R.;REEL/FRAME:036801/0127 Effective date: 20111010 |
|
AS | Assignment |
Owner name: LES HOPITAUX UNIVERSITAIRES DE GENEVE, SWITZERLAND Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE SECOND ASSIGNEE PREVIOUSLY RECORDED ON REEL 036801 FRAME 0102. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ENTIRE INTEREST;ASSIGNOR:DIETRICH, PIERRE-YVES;REEL/FRAME:037447/0281 Effective date: 20110305 Owner name: UNIVERSITE DE GENEVE, SWITZERLAND Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE SECOND ASSIGNEE PREVIOUSLY RECORDED ON REEL 036801 FRAME 0102. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ENTIRE INTEREST;ASSIGNOR:DIETRICH, PIERRE-YVES;REEL/FRAME:037447/0281 Effective date: 20110305 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |